Back to results

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Primary Purpose

Pulmonary Disease, Chronic Obstructive

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

fluticasone furoate (FF)

vilanterol (VI)

umeclidinium bromide (UMEC)

About this trial

This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive focused on measuring COPD, umeclidinium, fluticasone furoate, vilanterol, triple therapy, exacerbation

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Informed Consent: A signed and dated written informed consent prior to study participation
Type of subject: Outpatient
Age: Subjects 40 years of age or older at Visit 1
Gender: Male or female subjects. A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, > 45 years, in the absence of hormone replacement therapy OR Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to safety follow-up contact): Abstinence; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen; Implants of levonorgestrel; Estrogenic vaginal ring; Percutaneous contraceptive patches; Intrauterine device (IUD) or intrauterine system (IUS); Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records. Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
COPD Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society
Smoking History: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at screening (visit 1) [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history
Severity of COPD symptoms: A score of >=10 on the COPD Assessment Test (CAT) at screening
Severity of COPD Disease: A post-albuterol/salbutamol FEV1/ Forced Vital Capacity (FVC) ratio of <0.70 at Screening
Existing COPD maintenance treatment: Subject must be receiving daily maintenance treatment for their COPD for at least 3 months prior to Screening. Note: Subjects receiving only Pro re nata (PRN) COPD medications are not eligible
History of Exacerbations: Subjects must demonstrate: a post-bronchodilator FEV1 <50% predicted normal and a documented history of >= 1 moderate or severe COPD exacerbation in the previous 12 months OR a post-bronchodilator 50% <=FEV1 < 80% predicted normal and a documented history of >= 2 moderate exacerbations or a documented history of >=1 severe COPD exacerbation (hospitalized) in the previous 12 months. Note: Percent predicted will be calculated using the European Respiratory Society Global Lung Function Initiative reference equations. Note: A documented history of a COPD exacerbation (e.g., medical record verification) is a medical record of worsening COPD symptoms that required systemic/oral corticosteroids and/or antibiotics (for a moderate exacerbation) or hospitalization (for a severe exacerbation). Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are not acceptable
Liver function tests: alanine aminotransferase (ALT) <2x upper limit of normal (ULN); alkaline phosphatase <=1.5xULN; bilirubin <=1.5xULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category

Exclusion Criteria:

Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study
Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD)
Alpha1-antitrypsin deficiency: Subjects with Alpha1-antitrypsin deficiency as the underlying cause of COPD
Other respiratory disorders: Subjects with active tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening
Risk Factors for Pneumonia: immune suppression (e.g. human immunodeficiency virus [HIV], Lupus) or other risk factors for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's Disease, Myasthenia Gravis). Patients at potentially high risk (e.g. very low BMI, severely malnourished, or very low FEV1) will only be included at the discretion of the Investigator
Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 14 days prior to Screening and at least 30 days following the last dose of oral/systemic corticosteroids (if applicable). In addition, any subject that experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in period will be excluded
Other Respiratory tract infections that have not resolved at least 7 days prior to screening
Abnormal Chest x-ray(CXR): Chest x-ray (posteroanterior and lateral) reveals evidence of pneumonia or a clinically significant abnormality not believed to be due to the presence of COPD, or another condition that would hinder the ability to detect an infiltrate on CXR (e.g. significant cardiomegaly, pleural effusion or scarring). All subjects will have a chest x-ray at Screening Visit 1 (or historical radiograph or computerised tomography (CT) scan obtained within 3 months prior to screening) that will be over-read by a central vendor. Note: Subjects who have experienced pneumonia and/or moderate or severe COPD exacerbation within 3 months of screening must provide a post pneumonia/exacerbation chest x-ray to be over-read by the central vendor or have a chest x-ray conducted at screening. For sites in Germany: If a chest x-ray (or CT scan) within 3 months prior to Screening (Visit 1) is not available, approval to conduct a diagnostic chest x-ray will need to be obtained from the Federal Office for Radiation Protection (Bundesamt für Strahlenschutz [BfS])
Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study
Unstable liver disease as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
Note: Chronic stable hepatitis B and C are acceptable if the subject otherwise meets entry criteria
Unstable or life threatening cardiac disease: subjects with any of the following at Screening (Visit 1) would be excluded: Myocardial infarction or unstable angina in the last 6 months; Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months; New York Heart Association (NYHA) Class IV Heart failure
Abnormal and clinically significant 12-Lead Electrocardiogram (ECG) finding: Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. The Principal Investigator will determine the clinical significance of each abnormal ECG finding in relation to the subject's medical history and exclude subjects who would be at undue risk by participating in the trial. An abnormal and clinically significant finding that would preclude a subject from entering the trial is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following: atrial fibrillation (AF) with rapid ventricular rate >120 beats per minute); sustained or nonsustained ventricular tachycardia (VT); Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted); QT interval corrected for heart rate (QTcF) >=500 milliseconds (msec) in patients with QRS <120 msec and QTcF >=530 msec in patients with QRS >=120 msec
Contraindications: A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the Investigator contraindicates study participation
Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the subject has been considered cured by treatment
Oxygen therapy: Use of long-term oxygen therapy (LTOT) described as resting oxygen therapy >3 Liter/minute (L/min) (Oxygen use =<3L/min flow is not exclusionary)
Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol for the 4-hour period required prior to spirometry testing at each study visit
Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening or subjects who plan to enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded
Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years
Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits
Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study
Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or study site, or immediate family members of the aforementioned that is involved with this study
Inability to read: In the opinion of the Investigator, any subject who is unable to read and/or would not be able to complete study related materials
Medication prior to screening: Use of the following medications within the following time intervals prior to Screening (Visit 1) or during the study: Long term antibiotic therapy Subjects receiving antibiotics for long term therapy are not eligible for the study (Antibiotics are allowed for the short term treatment of an exacerbation or for short term treatment of other acute infections during the study); Systemic, Oral, parenteral corticosteroids 30 days (Except during the study oral/systemic corticosteroids may be used to treat COPD exacerbations/pneumonia) Intra-articular injections are allowed; Any other investigational drug (30 days or 5 half lives whichever is longer)

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Arm Label

fluticasone furoate/umeclidinium bromide/vilanterol

fluticasone furoate/vilanterol

umeclidinium bromide/vilanterol

Arm Description

Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI

Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)

Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI

Outcomes

Primary Outcome Measures

Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI

The annual rate of moderate or severe COPD exacerbations which occurred during treatment was assessed. Moderate exacerbations were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. Analysis performed using a generalized linear model assuming a negative binomial distribution. ITT population was used which comprised of all randomized participants, excluding those who were randomized in error. Only those participants with non-missing co-variates were included in the analysis.

Secondary Outcome Measures

Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1), at Week 52 Comparing FF/UMEC/VI With FF/VI

FEV1 was defined as the amount of air a person exhales in one second. Change from Baseline was calculated as the value of FEV1 at Week 52 minus the value at Baseline. Baseline for trough FEV1 was defined as Day 1 (Pre-dose). Only those participants with non-missing co-variates were included in the analysis. The analysis was performed using a Repeated measures model with covariates of treatment group, smoking status (Screening), geographical region, visit, Baseline, Baseline by visit and treatment group by visit interactions.

Change From Baseline in St. George's Respiratory Questionnaire for (SGRQ) Total Score at Week 52 Comparing FF/UMEC/VI With FF/VI

SGRQ is a disease specific-questionnaire, designed to measure impact of respiratory disease and its treatment on a COPD participant's Health Related Quality of Life (HRQoL). SGRQ contains 14 questions with total of 40 items grouped into three domains (Symptoms, Activity, and Impacts). The overall summary score along with scores for the individual domains of symptoms, activity and impacts were assessed. Score was calculated by summing the pre-assigned weights of answers, dividing by sum of maximum weights for items in SGRQ. Total scores ranged from 0 to 100. A decrease in score indicates improvement in HRQoL and higher score implies worse quality of life. Change from Baseline was calculated as total score at Week 52 minus value at Baseline. Baseline was defined as Day 1. Minimum clinically important difference (MCID) for this instrument is a 4-point improvement (decrease from Baseline). Only those participants with non-missing co-variates were included in the analysis.

Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With FF/VI and With UMEC/VI

This measures the number of days, to the first onset of moderate or severe exacerbations. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations, were defined as exacerbations that required hospitalization or resulted in death. The Hazard ratio from Cox proportional hazards model with covariates of treatment group, sex, exacerbation history (<=1, >=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted FEV1 (Screening), have been reported. Only those participants with non-missing co-variates were included in the analysis. First quartile and median time to onset are taken from the Kaplan-Meier estimates. If <25% (and <50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment.

Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI in the Subset of Participants With a Blood Eosinophil Count >=150 Cells Per Microliter

The annual rate of moderate or severe COPD exacerbations during the treatment, for participants with blood eosinophil count >=150 cells per microliter , has been reported. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. Only those participants with non-missing co-variates and non-missing eosinophil, at Baseline were included in the analysis.

Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With UMEC/VI in the Subset of Particpants With a Blood Eosinophil Count >=150 Cells Per Microliter at Baseline

This measures the number of days, to the first onset of moderate or severe exacerbations for participants with blood eosinophil count >=150 cells per microliter, at Baseline has been reported. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations, were defined as exacerbations that required hospitalization or resulted in death. Only those participants with non-missing co-variates and non missing eosinophils at Baseline were included in the analysis. First quartile and median time to onset are taken from the Kaplan-Meier estimates. If <25% (and <50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment.

Annual Rate of On-treatment Severe Exacerbations Comparing FF/UMEC/VI With FF/VI and With UMEC/VI

The annual rate of severe COPD exacerbations during the treatment, has been reported. Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. The covariates of treatment group, sex, exacerbation history (<=1, >=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted FEV1 (Screening) were used. Only those participants with non-missing co-variates were included in the analysis

Full Information

NCT ID

NCT02164513

First Posted

June 12, 2014

Last Updated

September 11, 2018

Sponsor

GlaxoSmithKline

1. Study Identification

Unique Protocol Identification Number

NCT02164513

Brief Title

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Official Title

A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

Study Type

Interventional

2. Study Status

Record Verification Date

August 2018

Overall Recruitment Status

Completed

Study Start Date

June 30, 2014 (Actual)

Primary Completion Date

July 17, 2017 (Actual)

Study Completion Date

July 17, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

GlaxoSmithKline

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Published studies which assessed the use of an 'open' triple therapy (use of Inhaled Corticosteroid [ICS]/ Long-acting Muscarinic Receptor Antagonists [LAMA])/ Long Acting Beta-Agonist [LABA] delivered via multiple inhalers) in moderate-severe COPD patients, reported improvements in lung function, Health Related Quality of Life (HRQoL), hospitalization rates and rescue medication use, compared to dual therapy (ICS/LABA) or LAMA alone. These studies have also shown similar safety profile with dual or monotherapy doses for periods of up to one year. Given the clinical experience with FF, UMEC and VI, and that the associated risks with these compounds are anticipated from their known pharmacology, the potential benefit of a new therapy option in patients with moderate to severe COPD supports the further development of the closed triple combination (delivered via one inhaler). In the current study subjects meeting all inclusion/exclusion criteria will complete 2-week run-in period; 52 week treatment period and a 1-week safety follow-up period. Eligible subjects will be randomized to one of the following double-blind treatment groups FF/UMEC/VI 100 micrograms (mcg)/62.5 mcg/25 mcg once daily (QD), FF/VI 100 mcg/25 mcg QD, or UMEC/VI 62.5 mcg/25 mcg QD

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Pulmonary Disease, Chronic Obstructive

Keywords

COPD, umeclidinium, fluticasone furoate, vilanterol, triple therapy, exacerbation

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigator

Allocation

Randomized

Enrollment

10355 (Actual)

8. Arms, Groups, and Interventions

Arm Title

fluticasone furoate/umeclidinium bromide/vilanterol

Arm Type

Experimental

Arm Description

Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI

Arm Title

fluticasone furoate/vilanterol

Arm Type

Experimental

Arm Description

Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)

Arm Title

umeclidinium bromide/vilanterol

Arm Type

Experimental

Arm Description

Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI

Intervention Type

Drug

Intervention Name(s)

fluticasone furoate (FF)

Intervention Description

FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg

Intervention Type

Drug

Intervention Name(s)

vilanterol (VI)

Intervention Description

VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg

Intervention Type

Drug

Intervention Name(s)

umeclidinium bromide (UMEC)

Intervention Description

UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg

Primary Outcome Measure Information:

Title

Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI

Description

Time Frame

Up to Week 52

Secondary Outcome Measure Information:

Title

Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1), at Week 52 Comparing FF/UMEC/VI With FF/VI

Description

Time Frame

Baseline and Week 52

Title

Change From Baseline in St. George's Respiratory Questionnaire for (SGRQ) Total Score at Week 52 Comparing FF/UMEC/VI With FF/VI

Description

Time Frame

Baseline and Week 52

Title

Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With FF/VI and With UMEC/VI

Description

Time Frame

Up to Week 52

Title

Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI in the Subset of Participants With a Blood Eosinophil Count >=150 Cells Per Microliter

Description

Time Frame

Up to Week 52

Title

Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With UMEC/VI in the Subset of Particpants With a Blood Eosinophil Count >=150 Cells Per Microliter at Baseline

Description

Time Frame

Up to Week 52

Title

Annual Rate of On-treatment Severe Exacerbations Comparing FF/UMEC/VI With FF/VI and With UMEC/VI

Description

Time Frame

Up to Week 52

10. Eligibility

Sex

All

Minimum Age & Unit of Time

40 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Informed Consent: A signed and dated written informed consent prior to study participation Type of subject: Outpatient Age: Subjects 40 years of age or older at Visit 1 Gender: Male or female subjects. A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, > 45 years, in the absence of hormone replacement therapy OR Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to safety follow-up contact): Abstinence; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen; Implants of levonorgestrel; Estrogenic vaginal ring; Percutaneous contraceptive patches; Intrauterine device (IUD) or intrauterine system (IUS); Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records. Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository) COPD Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society Smoking History: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at screening (visit 1) [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history Severity of COPD symptoms: A score of >=10 on the COPD Assessment Test (CAT) at screening Severity of COPD Disease: A post-albuterol/salbutamol FEV1/ Forced Vital Capacity (FVC) ratio of <0.70 at Screening Existing COPD maintenance treatment: Subject must be receiving daily maintenance treatment for their COPD for at least 3 months prior to Screening. Note: Subjects receiving only Pro re nata (PRN) COPD medications are not eligible History of Exacerbations: Subjects must demonstrate: a post-bronchodilator FEV1 <50% predicted normal and a documented history of >= 1 moderate or severe COPD exacerbation in the previous 12 months OR a post-bronchodilator 50% <=FEV1 < 80% predicted normal and a documented history of >= 2 moderate exacerbations or a documented history of >=1 severe COPD exacerbation (hospitalized) in the previous 12 months. Note: Percent predicted will be calculated using the European Respiratory Society Global Lung Function Initiative reference equations. Note: A documented history of a COPD exacerbation (e.g., medical record verification) is a medical record of worsening COPD symptoms that required systemic/oral corticosteroids and/or antibiotics (for a moderate exacerbation) or hospitalization (for a severe exacerbation). Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are not acceptable Liver function tests: alanine aminotransferase (ALT) <2x upper limit of normal (ULN); alkaline phosphatase <=1.5xULN; bilirubin <=1.5xULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%) French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category Exclusion Criteria: Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD) Alpha1-antitrypsin deficiency: Subjects with Alpha1-antitrypsin deficiency as the underlying cause of COPD Other respiratory disorders: Subjects with active tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening Risk Factors for Pneumonia: immune suppression (e.g. human immunodeficiency virus [HIV], Lupus) or other risk factors for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's Disease, Myasthenia Gravis). Patients at potentially high risk (e.g. very low BMI, severely malnourished, or very low FEV1) will only be included at the discretion of the Investigator Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 14 days prior to Screening and at least 30 days following the last dose of oral/systemic corticosteroids (if applicable). In addition, any subject that experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in period will be excluded Other Respiratory tract infections that have not resolved at least 7 days prior to screening Abnormal Chest x-ray(CXR): Chest x-ray (posteroanterior and lateral) reveals evidence of pneumonia or a clinically significant abnormality not believed to be due to the presence of COPD, or another condition that would hinder the ability to detect an infiltrate on CXR (e.g. significant cardiomegaly, pleural effusion or scarring). All subjects will have a chest x-ray at Screening Visit 1 (or historical radiograph or computerised tomography (CT) scan obtained within 3 months prior to screening) that will be over-read by a central vendor. Note: Subjects who have experienced pneumonia and/or moderate or severe COPD exacerbation within 3 months of screening must provide a post pneumonia/exacerbation chest x-ray to be over-read by the central vendor or have a chest x-ray conducted at screening. For sites in Germany: If a chest x-ray (or CT scan) within 3 months prior to Screening (Visit 1) is not available, approval to conduct a diagnostic chest x-ray will need to be obtained from the Federal Office for Radiation Protection (Bundesamt für Strahlenschutz [BfS]) Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study Unstable liver disease as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Note: Chronic stable hepatitis B and C are acceptable if the subject otherwise meets entry criteria Unstable or life threatening cardiac disease: subjects with any of the following at Screening (Visit 1) would be excluded: Myocardial infarction or unstable angina in the last 6 months; Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months; New York Heart Association (NYHA) Class IV Heart failure Abnormal and clinically significant 12-Lead Electrocardiogram (ECG) finding: Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. The Principal Investigator will determine the clinical significance of each abnormal ECG finding in relation to the subject's medical history and exclude subjects who would be at undue risk by participating in the trial. An abnormal and clinically significant finding that would preclude a subject from entering the trial is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following: atrial fibrillation (AF) with rapid ventricular rate >120 beats per minute); sustained or nonsustained ventricular tachycardia (VT); Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted); QT interval corrected for heart rate (QTcF) >=500 milliseconds (msec) in patients with QRS <120 msec and QTcF >=530 msec in patients with QRS >=120 msec Contraindications: A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the Investigator contraindicates study participation Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the subject has been considered cured by treatment Oxygen therapy: Use of long-term oxygen therapy (LTOT) described as resting oxygen therapy >3 Liter/minute (L/min) (Oxygen use =<3L/min flow is not exclusionary) Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol for the 4-hour period required prior to spirometry testing at each study visit Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening or subjects who plan to enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or study site, or immediate family members of the aforementioned that is involved with this study Inability to read: In the opinion of the Investigator, any subject who is unable to read and/or would not be able to complete study related materials Medication prior to screening: Use of the following medications within the following time intervals prior to Screening (Visit 1) or during the study: Long term antibiotic therapy Subjects receiving antibiotics for long term therapy are not eligible for the study (Antibiotics are allowed for the short term treatment of an exacerbation or for short term treatment of other acute infections during the study); Systemic, Oral, parenteral corticosteroids 30 days (Except during the study oral/systemic corticosteroids may be used to treat COPD exacerbations/pneumonia) Intra-articular injections are allowed; Any other investigational drug (30 days or 5 half lives whichever is longer)

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

GSK Clinical Trials

Organizational Affiliation

GlaxoSmithKline

Official's Role

Study Director

Facility Information:

Facility Name

GSK Investigational Site

City

Athens

State/Province

Alabama

ZIP/Postal Code

35611

Country

United States

Facility Name

GSK Investigational Site

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35215

Country

United States

Facility Name

GSK Investigational Site

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35216

Country

United States

Facility Name

GSK Investigational Site

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35294

Country

United States

Facility Name

GSK Investigational Site

City

Florence

State/Province

Alabama

ZIP/Postal Code

35630

Country

United States

Facility Name

GSK Investigational Site

City

Jasper

State/Province

Alabama

ZIP/Postal Code

35501

Country

United States

Facility Name

GSK Investigational Site

City

Mobile

State/Province

Alabama

ZIP/Postal Code

36608

Country

United States

Facility Name

GSK Investigational Site

City

Muscle Shoals

State/Province

Alabama

ZIP/Postal Code

35662

Country

United States

Facility Name

GSK Investigational Site

City

Sheffield

State/Province

Alabama

ZIP/Postal Code

35660

Country

United States

Facility Name

GSK Investigational Site

City

Chandler

State/Province

Arizona

ZIP/Postal Code

85284

Country

United States

Facility Name

GSK Investigational Site

City

Flagstaff

State/Province

Arizona

ZIP/Postal Code

86001

Country

United States

Facility Name

GSK Investigational Site

City

Glendale

State/Province

Arizona

ZIP/Postal Code

85306

Country

United States

Facility Name

GSK Investigational Site

City

Peoria

State/Province

Arizona

ZIP/Postal Code

85381

Country

United States

Facility Name

GSK Investigational Site

City

Phoenix

State/Province

Arizona

ZIP/Postal Code

85018

Country

United States

Facility Name

GSK Investigational Site

City

Phoenix

State/Province

Arizona

ZIP/Postal Code

85032

Country

United States

Facility Name

GSK Investigational Site

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85723

Country

United States

Facility Name

GSK Investigational Site

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85724-5023

Country

United States

Facility Name

GSK Investigational Site

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85745

Country

United States

Facility Name

GSK Investigational Site

City

Arcadia

State/Province

California

ZIP/Postal Code

91007

Country

United States

Facility Name

GSK Investigational Site

City

Bakersfield

State/Province

California

ZIP/Postal Code

93301

Country

United States

Facility Name

GSK Investigational Site

City

Chula Vista

State/Province

California

ZIP/Postal Code

91910

Country

United States

Facility Name

GSK Investigational Site

City

Encinitas

State/Province

California

ZIP/Postal Code

92024

Country

United States

Facility Name

GSK Investigational Site

City

Escondido

State/Province

California

ZIP/Postal Code

92025

Country

United States

Facility Name

GSK Investigational Site

City

Huntington Beach

State/Province

California

ZIP/Postal Code

92647

Country

United States

Facility Name

GSK Investigational Site

City

Long Beach

State/Province

California

ZIP/Postal Code

90808

Country

United States

Facility Name

GSK Investigational Site

City

Long Beach

State/Province

California

ZIP/Postal Code

90822

Country

United States

Facility Name

GSK Investigational Site

City

Mission Hills

State/Province

California

ZIP/Postal Code

91345

Country

United States

Facility Name

GSK Investigational Site

City

Modesto

State/Province

California

ZIP/Postal Code

95350

Country

United States

Facility Name

GSK Investigational Site

City

Newport Beach

State/Province

California

ZIP/Postal Code

92663

Country

United States

Facility Name

GSK Investigational Site

City

Palo Alto

State/Province

California

ZIP/Postal Code

94304

Country

United States

Facility Name

GSK Investigational Site

City

Reseda

State/Province

California

ZIP/Postal Code

91335

Country

United States

Facility Name

GSK Investigational Site

City

Riverside

State/Province

California

ZIP/Postal Code

92506

Country

United States

Facility Name

GSK Investigational Site

City

Rolling Hills Estates

State/Province

California

ZIP/Postal Code

90274

Country

United States

Facility Name

GSK Investigational Site

City

Sacramento

State/Province

California

ZIP/Postal Code

95821

Country

United States

Facility Name

GSK Investigational Site

City

San Diego

State/Province

California

ZIP/Postal Code

92117

Country

United States

Facility Name

GSK Investigational Site

City

Santa Ana

State/Province

California

ZIP/Postal Code

92705

Country

United States

Facility Name

GSK Investigational Site

City

Santa Monica

State/Province

California

ZIP/Postal Code

90404

Country

United States

Facility Name

GSK Investigational Site

City

Torrance

State/Province

California

ZIP/Postal Code

90505

Country

United States

Facility Name

GSK Investigational Site

City

Tustin

State/Province

California

ZIP/Postal Code

92780

Country

United States

Facility Name

GSK Investigational Site

City

Upland

State/Province

California

ZIP/Postal Code

91786

Country

United States

Facility Name

GSK Investigational Site

City

Vista

State/Province

California

ZIP/Postal Code

92083

Country

United States

Facility Name

GSK Investigational Site

City

Boulder

State/Province

Colorado

ZIP/Postal Code

80301

Country

United States

Facility Name

GSK Investigational Site

City

Colorado Springs

State/Province

Colorado

ZIP/Postal Code

80907

Country

United States

Facility Name

GSK Investigational Site

City

Fort Collins

State/Province

Colorado

ZIP/Postal Code

80538

Country

United States

Facility Name

GSK Investigational Site

City

Golden

State/Province

Colorado

ZIP/Postal Code

80401

Country

United States

Facility Name

GSK Investigational Site

City

Danbury

State/Province

Connecticut

ZIP/Postal Code

06810

Country

United States

Facility Name

GSK Investigational Site

City

Hartford

State/Province

Connecticut

ZIP/Postal Code

06105

Country

United States

Facility Name

GSK Investigational Site

City

New Haven

State/Province

Connecticut

ZIP/Postal Code

06520

Country

United States

Facility Name

GSK Investigational Site

City

Stamford

State/Province

Connecticut

ZIP/Postal Code

06902

Country

United States

Facility Name

GSK Investigational Site

City

Waterbury

State/Province

Connecticut

ZIP/Postal Code

06708

Country

United States

Facility Name

GSK Investigational Site

City

West Haven

State/Province

Connecticut

ZIP/Postal Code

06516

Country

United States

Facility Name

GSK Investigational Site

City

Bay Pines

State/Province

Florida

ZIP/Postal Code

33744

Country

United States

Facility Name

GSK Investigational Site

City

Boynton Beach

State/Province

Florida

ZIP/Postal Code

33436

Country

United States

Facility Name

GSK Investigational Site

City

Brandon

State/Province

Florida

ZIP/Postal Code

33511

Country

United States

Facility Name

GSK Investigational Site

City

Celebration

State/Province

Florida

ZIP/Postal Code

34747

Country

United States

Facility Name

GSK Investigational Site

City

Clearwater

State/Province

Florida

ZIP/Postal Code

33759

Country

United States

Facility Name

GSK Investigational Site

City

Clearwater

State/Province

Florida

ZIP/Postal Code

33765-2616

Country

United States

Facility Name

GSK Investigational Site

City

Daytona Beach

State/Province

Florida

ZIP/Postal Code

32117

Country

United States

Facility Name

GSK Investigational Site

City

DeLand

State/Province

Florida

ZIP/Postal Code

32720

Country

United States

Facility Name

GSK Investigational Site

City

Edgewater

State/Province

Florida

ZIP/Postal Code

32132

Country

United States

Facility Name

GSK Investigational Site

City

Fort Lauderdale

State/Province

Florida

ZIP/Postal Code

33306

Country

United States

Facility Name

GSK Investigational Site

City

Fort Myers

State/Province

Florida

ZIP/Postal Code

33908

Country

United States

Facility Name

GSK Investigational Site

City

Gainesville

State/Province

Florida

ZIP/Postal Code

32608

Country

United States

Facility Name

GSK Investigational Site

City

Hollywood

State/Province

Florida

ZIP/Postal Code

33024

Country

United States

Facility Name

GSK Investigational Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32204

Country

United States

Facility Name

GSK Investigational Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32205

Country

United States

Facility Name

GSK Investigational Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32207

Country

United States

Facility Name

GSK Investigational Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32209

Country

United States

Facility Name

GSK Investigational Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32216

Country

United States

Facility Name

GSK Investigational Site

City

Leesburg

State/Province

Florida

ZIP/Postal Code

34748

Country

United States

Facility Name

GSK Investigational Site

City

Loxahatchee Groves

State/Province

Florida

ZIP/Postal Code

33470

Country

United States

Facility Name

GSK Investigational Site

City

Maitland

State/Province

Florida

ZIP/Postal Code

32751

Country

United States

Facility Name

GSK Investigational Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33015

Country

United States

Facility Name

GSK Investigational Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33137

Country

United States

Facility Name

GSK Investigational Site

City

New Port Richey

State/Province

Florida

ZIP/Postal Code

34652

Country

United States

Facility Name

GSK Investigational Site

City

Orlando

State/Province

Florida

ZIP/Postal Code

32825

Country

United States

Facility Name

GSK Investigational Site

City

Oviedo

State/Province

Florida

ZIP/Postal Code

32765

Country

United States

Facility Name

GSK Investigational Site

City

Pembroke Pines

State/Province

Florida

ZIP/Postal Code

33027

Country

United States

Facility Name

GSK Investigational Site

City

Pensacola

State/Province

Florida

ZIP/Postal Code

32503

Country

United States

Facility Name

GSK Investigational Site

City

Ponte Vedra Beach

State/Province

Florida

ZIP/Postal Code

32081

Country

United States

Facility Name

GSK Investigational Site

City

Port Charlotte

State/Province

Florida

ZIP/Postal Code

33952

Country

United States

Facility Name

GSK Investigational Site

City

Port Charlotte

State/Province

Florida

ZIP/Postal Code

33980

Country

United States

Facility Name

GSK Investigational Site

City

Port Orange

State/Province

Florida

ZIP/Postal Code

32127

Country

United States

Facility Name

GSK Investigational Site

City

Saint Petersburg

State/Province

Florida

ZIP/Postal Code

33704

Country

United States

Facility Name

GSK Investigational Site

City

Sarasota

State/Province

Florida

ZIP/Postal Code

34239

Country

United States

Facility Name

GSK Investigational Site

City

Tampa

State/Province

Florida

ZIP/Postal Code

33603

Country

United States

Facility Name

GSK Investigational Site

City

Adairsville

State/Province

Georgia

ZIP/Postal Code

30103

Country

United States

Facility Name

GSK Investigational Site

City

Athens

State/Province

Georgia

ZIP/Postal Code

30606

Country

United States

Facility Name

GSK Investigational Site

City

Austell

State/Province

Georgia

ZIP/Postal Code

30106

Country

United States

Facility Name

GSK Investigational Site

City

Columbus

State/Province

Georgia

ZIP/Postal Code

31904

Country

United States

Facility Name

GSK Investigational Site

City

Conyers

State/Province

Georgia

ZIP/Postal Code

30094

Country

United States

Facility Name

GSK Investigational Site

City

Decatur

State/Province

Georgia

ZIP/Postal Code

30033

Country

United States

Facility Name

GSK Investigational Site

City

Duluth

State/Province

Georgia

ZIP/Postal Code

30096

Country

United States

Facility Name

GSK Investigational Site

City

Gainesville

State/Province

Georgia

ZIP/Postal Code

30501

Country

United States

Facility Name

GSK Investigational Site

City

Marietta

State/Province

Georgia

ZIP/Postal Code

30060

Country

United States

Facility Name

GSK Investigational Site

City

Rincon

State/Province

Georgia

ZIP/Postal Code

31326

Country

United States

Facility Name

GSK Investigational Site

City

Woodstock

State/Province

Georgia

ZIP/Postal Code

30189

Country

United States

Facility Name

GSK Investigational Site

City

Coeur d'Alene

State/Province

Idaho

ZIP/Postal Code

83814

Country

United States

Facility Name

GSK Investigational Site

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60611

Country

United States

Facility Name

GSK Investigational Site

City

Elk Grove Village

State/Province

Illinois

ZIP/Postal Code

60007

Country

United States

Facility Name

GSK Investigational Site

City

Gillespie

State/Province

Illinois

ZIP/Postal Code

62033

Country

United States

Facility Name

GSK Investigational Site

City

Hines

State/Province

Illinois

ZIP/Postal Code

60124

Country

United States

Facility Name

GSK Investigational Site

City

O'Fallon

State/Province

Illinois

ZIP/Postal Code

62269

Country

United States

Facility Name

GSK Investigational Site

City

Oak Park

State/Province

Illinois

ZIP/Postal Code

60302

Country

United States

Facility Name

GSK Investigational Site

City

Quincy

State/Province

Illinois

ZIP/Postal Code

62301

Country

United States

Facility Name

GSK Investigational Site

City

Winfield

State/Province

Illinois

ZIP/Postal Code

60190

Country

United States

Facility Name

GSK Investigational Site

City

Evansville

State/Province

Indiana

ZIP/Postal Code

47714

Country

United States

Facility Name

GSK Investigational Site

City

Franklin

State/Province

Indiana

ZIP/Postal Code

46131

Country

United States

Facility Name

GSK Investigational Site

City

Greenfield

State/Province

Indiana

ZIP/Postal Code

46140

Country

United States

Facility Name

GSK Investigational Site

City

Muncie

State/Province

Indiana

ZIP/Postal Code

47303

Country

United States

Facility Name

GSK Investigational Site

City

Council Bluffs

State/Province

Iowa

ZIP/Postal Code

51503

Country

United States

Facility Name

GSK Investigational Site

City

Iowa City

State/Province

Iowa

ZIP/Postal Code

52242

Country

United States

Facility Name

GSK Investigational Site

City

Olathe

State/Province

Kansas

ZIP/Postal Code

66061

Country

United States

Facility Name

GSK Investigational Site

City

Topeka

State/Province

Kansas

ZIP/Postal Code

66606

Country

United States

Facility Name

GSK Investigational Site

City

Wichita

State/Province

Kansas

ZIP/Postal Code

67218

Country

United States

Facility Name

GSK Investigational Site

City

Fort Mitchell

State/Province

Kentucky

ZIP/Postal Code

41017

Country

United States

Facility Name

GSK Investigational Site

City

Louisville

State/Province

Kentucky

ZIP/Postal Code

40218

Country

United States

Facility Name

GSK Investigational Site

City

Paducah

State/Province

Kentucky

ZIP/Postal Code

42003

Country

United States

Facility Name

GSK Investigational Site

City

Crowley

State/Province

Louisiana

ZIP/Postal Code

70526

Country

United States

Facility Name

GSK Investigational Site

City

Lafayette

State/Province

Louisiana

ZIP/Postal Code

70508

Country

United States

Facility Name

GSK Investigational Site

City

New Orleans

State/Province

Louisiana

ZIP/Postal Code

70112

Country

United States

Facility Name

GSK Investigational Site

City

New Orleans

State/Province

Louisiana

ZIP/Postal Code

70115

Country

United States

Facility Name

GSK Investigational Site

City

New Orleans

State/Province

Louisiana

ZIP/Postal Code

70119

Country

United States

Facility Name

GSK Investigational Site

City

Shreveport

State/Province

Louisiana

ZIP/Postal Code

71103

Country

United States

Facility Name

GSK Investigational Site

City

Sunset

State/Province

Louisiana

ZIP/Postal Code

70584

Country

United States

Facility Name

GSK Investigational Site

City

Bangor

State/Province

Maine

ZIP/Postal Code

04401

Country

United States

Facility Name

GSK Investigational Site

City

Columbia

State/Province

Maryland

ZIP/Postal Code

21044

Country

United States

Facility Name

GSK Investigational Site

City

Hollywood

State/Province

Maryland

ZIP/Postal Code

20636

Country

United States

Facility Name

GSK Investigational Site

City

Fall River

State/Province

Massachusetts

ZIP/Postal Code

02720

Country

United States

Facility Name

GSK Investigational Site

City

North Dartmouth

State/Province

Massachusetts

ZIP/Postal Code

02747

Country

United States

Facility Name

GSK Investigational Site

City

Pittsfield

State/Province

Massachusetts

ZIP/Postal Code

01201

Country

United States

Facility Name

GSK Investigational Site

City

Worcester

State/Province

Massachusetts

ZIP/Postal Code

01608

Country

United States

Facility Name

GSK Investigational Site

City

Ann Arbor

State/Province

Michigan

ZIP/Postal Code

48106

Country

United States

Facility Name

GSK Investigational Site

City

Southfield

State/Province

Michigan

ZIP/Postal Code

48034

Country

United States

Facility Name

GSK Investigational Site

City

Troy

State/Province

Michigan

ZIP/Postal Code

48085

Country

United States

Facility Name

GSK Investigational Site

City

Duluth

State/Province

Minnesota

ZIP/Postal Code

55805

Country

United States

Facility Name

GSK Investigational Site

City

Edina

State/Province

Minnesota

ZIP/Postal Code

55435

Country

United States

Facility Name

GSK Investigational Site

City

Fridley

State/Province

Minnesota

ZIP/Postal Code

55432

Country

United States

Facility Name

GSK Investigational Site

City

Minneapolis

State/Province

Minnesota

ZIP/Postal Code

55402

Country

United States

Facility Name

GSK Investigational Site

City

Minneapolis

State/Province

Minnesota

ZIP/Postal Code

55407

Country

United States

Facility Name

GSK Investigational Site

City

Rochester

State/Province

Minnesota

ZIP/Postal Code

55905

Country

United States

Facility Name

GSK Investigational Site

City

Saint Paul

State/Province

Minnesota

ZIP/Postal Code

55130

Country

United States

Facility Name

GSK Investigational Site

City

Woodbury

State/Province

Minnesota

ZIP/Postal Code

55125

Country

United States

Facility Name

GSK Investigational Site

City

Jackson

State/Province

Mississippi

ZIP/Postal Code

39202

Country

United States

Facility Name

GSK Investigational Site

City

Chesterfield

State/Province

Missouri

ZIP/Postal Code

63017

Country

United States

Facility Name

GSK Investigational Site

City

Kansas City

State/Province

Missouri

ZIP/Postal Code

64128

Country

United States

Facility Name

GSK Investigational Site

City

Saint Charles

State/Province

Missouri

ZIP/Postal Code

63301

Country

United States

Facility Name

GSK Investigational Site

City

Saint Louis

State/Province

Missouri

ZIP/Postal Code

63141

Country

United States

Facility Name

GSK Investigational Site

City

Butte

State/Province

Montana

ZIP/Postal Code

59701

Country

United States

Facility Name

GSK Investigational Site

City

Missoula

State/Province

Montana

ZIP/Postal Code

59808

Country

United States

Facility Name

GSK Investigational Site

City

Fremont

State/Province

Nebraska

ZIP/Postal Code

68025

Country

United States

Facility Name

GSK Investigational Site

City

Grand Island

State/Province

Nebraska

ZIP/Postal Code

68803

Country

United States

Facility Name

GSK Investigational Site

City

Lincoln

State/Province

Nebraska

ZIP/Postal Code

68506

Country

United States

Facility Name

GSK Investigational Site

City

Omaha

State/Province

Nebraska

ZIP/Postal Code

68131

Country

United States

Facility Name

GSK Investigational Site

City

Omaha

State/Province

Nebraska

ZIP/Postal Code

68134

Country

United States

Facility Name

GSK Investigational Site

City

Las Vegas

State/Province

Nevada

ZIP/Postal Code

89106

Country

United States

Facility Name

GSK Investigational Site

City

Reno

State/Province

Nevada

ZIP/Postal Code

89503

Country

United States

Facility Name

GSK Investigational Site

City

Marlton

State/Province

New Jersey

ZIP/Postal Code

08053

Country

United States

Facility Name

GSK Investigational Site

City

Moorestown

State/Province

New Jersey

ZIP/Postal Code

08057

Country

United States

Facility Name

GSK Investigational Site

City

Neptune

State/Province

New Jersey

ZIP/Postal Code

07753

Country

United States

Facility Name

GSK Investigational Site

City

Albuquerque

State/Province

New Mexico

ZIP/Postal Code

87108

Country

United States

Facility Name

GSK Investigational Site

City

Albany

State/Province

New York

ZIP/Postal Code

12208

Country

United States

Facility Name

GSK Investigational Site

City

Bronxville

State/Province

New York

ZIP/Postal Code

10708

Country

United States

Facility Name

GSK Investigational Site

City

Bronx

State/Province

New York

ZIP/Postal Code

10457

Country

United States

Facility Name

GSK Investigational Site

City

Bronx

State/Province

New York

ZIP/Postal Code

10461

Country

United States

Facility Name

GSK Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10009

Country

United States

Facility Name

GSK Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10016

Country

United States

Facility Name

GSK Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10029

Country

United States

Facility Name

GSK Investigational Site

City

Syracuse

State/Province

New York

ZIP/Postal Code

13210

Country

United States

Facility Name

GSK Investigational Site

City

Asheville

State/Province

North Carolina

ZIP/Postal Code

28801

Country

United States

Facility Name

GSK Investigational Site

City

Calabash

State/Province

North Carolina

ZIP/Postal Code

28467

Country

United States

Facility Name

GSK Investigational Site

City

Charlotte

State/Province

North Carolina

ZIP/Postal Code

28207

Country

United States

Facility Name

GSK Investigational Site

City

Charlotte

State/Province

North Carolina

ZIP/Postal Code

28262

Country

United States

Facility Name

GSK Investigational Site

City

Charlotte

State/Province

North Carolina

ZIP/Postal Code

28277

Country

United States

Facility Name

GSK Investigational Site

City

Durham

State/Province

North Carolina

ZIP/Postal Code

27710

Country

United States

Facility Name

GSK Investigational Site

City

Elizabeth City

State/Province

North Carolina

ZIP/Postal Code

27909

Country

United States

Facility Name

GSK Investigational Site

City

Gastonia

State/Province

North Carolina

ZIP/Postal Code

28054

Country

United States

Facility Name

GSK Investigational Site

City

Greensboro

State/Province

North Carolina

ZIP/Postal Code

27403

Country

United States

Facility Name

GSK Investigational Site

City

Hendersonville

State/Province

North Carolina

ZIP/Postal Code

28739

Country

United States

Facility Name

GSK Investigational Site

City

Huntersville

State/Province

North Carolina

ZIP/Postal Code

28078

Country

United States

Facility Name

GSK Investigational Site

City

Lexington

State/Province

North Carolina

ZIP/Postal Code

27292

Country

United States

Facility Name

GSK Investigational Site

City

Mooresville

State/Province

North Carolina

ZIP/Postal Code

28117

Country

United States

Facility Name

GSK Investigational Site

City

Shelby

State/Province

North Carolina

ZIP/Postal Code

28150

Country

United States

Facility Name

GSK Investigational Site

City

Shelby

State/Province

North Carolina

ZIP/Postal Code

28152

Country

United States

Facility Name

GSK Investigational Site

City

Tabor City

State/Province

North Carolina

ZIP/Postal Code

28463

Country

United States

Facility Name

GSK Investigational Site

City

Whiteville

State/Province

North Carolina

ZIP/Postal Code

28472

Country

United States

Facility Name

GSK Investigational Site

City

Wilmington

State/Province

North Carolina

ZIP/Postal Code

28401

Country

United States

Facility Name

GSK Investigational Site

City

Winston-Salem

State/Province

North Carolina

ZIP/Postal Code

27103

Country

United States

Facility Name

GSK Investigational Site

City

Canton

State/Province

Ohio

ZIP/Postal Code

44718

Country

United States

Facility Name

GSK Investigational Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45220

Country

United States

Facility Name

GSK Investigational Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45231

Country

United States

Facility Name

GSK Investigational Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45245

Country

United States

Facility Name

GSK Investigational Site

City

Columbus

State/Province

Ohio

ZIP/Postal Code

43213

Country

United States

Facility Name

GSK Investigational Site

City

Dayton

State/Province

Ohio

ZIP/Postal Code

45459

Country

United States

Facility Name

GSK Investigational Site

City

Marion

State/Province

Ohio

ZIP/Postal Code

43302

Country

United States

Facility Name

GSK Investigational Site

City

Middleburg Heights

State/Province

Ohio

ZIP/Postal Code

44130

Country

United States

Facility Name

GSK Investigational Site

City

Toledo

State/Province

Ohio

ZIP/Postal Code

43606

Country

United States

Facility Name

GSK Investigational Site

City

Toledo

State/Province

Ohio

ZIP/Postal Code

43617

Country

United States

Facility Name

GSK Investigational Site

City

Wooster

State/Province

Ohio

ZIP/Postal Code

44691

Country

United States

Facility Name

GSK Investigational Site

City

Corvallis

State/Province

Oregon

ZIP/Postal Code

97330

Country

United States

Facility Name

GSK Investigational Site

City

Medford

State/Province

Oregon

ZIP/Postal Code

97504

Country

United States

Facility Name

GSK Investigational Site

City

Portland

State/Province

Oregon

ZIP/Postal Code

97220

Country

United States

Facility Name

GSK Investigational Site

City

Portland

State/Province

Oregon

ZIP/Postal Code

97225

Country

United States

Facility Name

GSK Investigational Site

City

Portland

State/Province

Oregon

ZIP/Postal Code

97239

Country

United States

Facility Name

GSK Investigational Site

City

Downingtown

State/Province

Pennsylvania

ZIP/Postal Code

19335

Country

United States

Facility Name

GSK Investigational Site

City

Doylestown

State/Province

Pennsylvania

ZIP/Postal Code

18901

Country

United States

Facility Name

GSK Investigational Site

City

Erie

State/Province

Pennsylvania

ZIP/Postal Code

16508

Country

United States

Facility Name

GSK Investigational Site

City

Johnstown

State/Province

Pennsylvania

ZIP/Postal Code

15905

Country

United States

Facility Name

GSK Investigational Site

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19107

Country

United States

Facility Name

GSK Investigational Site

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19140

Country

United States

Facility Name

GSK Investigational Site

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19142

Country

United States

Facility Name

GSK Investigational Site

City

Phoenixville

State/Province

Pennsylvania

ZIP/Postal Code

19460

Country

United States

Facility Name

GSK Investigational Site

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15213

Country

United States

Facility Name

GSK Investigational Site

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15241

Country

United States

Facility Name

GSK Investigational Site

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15243

Country

United States

Facility Name

GSK Investigational Site

City

Tipton

State/Province

Pennsylvania

ZIP/Postal Code

16684

Country

United States

Facility Name

GSK Investigational Site

City

Wyomissing

State/Province

Pennsylvania

ZIP/Postal Code

19610

Country

United States

Facility Name

GSK Investigational Site

City

East Providence

State/Province

Rhode Island

ZIP/Postal Code

02914

Country

United States

Facility Name

GSK Investigational Site

City

Anderson

State/Province

South Carolina

ZIP/Postal Code

29621

Country

United States

Facility Name

GSK Investigational Site

City

Charleston

State/Province

South Carolina

ZIP/Postal Code

29406-7108

Country

United States

Facility Name

GSK Investigational Site

City

Columbia

State/Province

South Carolina

ZIP/Postal Code

29204

Country

United States

Facility Name

GSK Investigational Site

City

Columbia

State/Province

South Carolina

ZIP/Postal Code

29209

Country

United States

Facility Name

GSK Investigational Site

City

Easley

State/Province

South Carolina

ZIP/Postal Code

29640

Country

United States

Facility Name

GSK Investigational Site

City

Fort Mill

State/Province

South Carolina

ZIP/Postal Code

29707

Country

United States

Facility Name

GSK Investigational Site

City

Gaffney

State/Province

South Carolina

ZIP/Postal Code

29340

Country

United States

Facility Name

GSK Investigational Site

City

Gaffney

State/Province

South Carolina

ZIP/Postal Code

29341

Country

United States

Facility Name

GSK Investigational Site

City

Greenville

State/Province

South Carolina

ZIP/Postal Code

29615

Country

United States

Facility Name

GSK Investigational Site

City

Mount Pleasant

State/Province

South Carolina

ZIP/Postal Code

29464

Country

United States

Facility Name

GSK Investigational Site

City

Rock Hill

State/Province

South Carolina

ZIP/Postal Code

29732

Country

United States

Facility Name

GSK Investigational Site

City

Seneca

State/Province

South Carolina

ZIP/Postal Code

29678

Country

United States

Facility Name

GSK Investigational Site

City

Spartanburg

State/Province

South Carolina

ZIP/Postal Code

29303

Country

United States

Facility Name

GSK Investigational Site

City

Union

State/Province

South Carolina

ZIP/Postal Code

29379

Country

United States

Facility Name

GSK Investigational Site

City

Rapid City

State/Province

South Dakota

ZIP/Postal Code

57702

Country

United States

Facility Name

GSK Investigational Site

City

Sioux Falls

State/Province

South Dakota

ZIP/Postal Code

57108

Country

United States

Facility Name

GSK Investigational Site

City

Chattanooga

State/Province

Tennessee

ZIP/Postal Code

37404

Country

United States

Facility Name

GSK Investigational Site

City

Hendersonville

State/Province

Tennessee

ZIP/Postal Code

37075

Country

United States

Facility Name

GSK Investigational Site

City

Johnson City

State/Province

Tennessee

ZIP/Postal Code

37601

Country

United States

Facility Name

GSK Investigational Site

City

Corsicana

State/Province

Texas

ZIP/Postal Code

75110

Country

United States

Facility Name

GSK Investigational Site

City

Edinburg

State/Province

Texas

ZIP/Postal Code

78539

Country

United States

Facility Name

GSK Investigational Site

City

Fort Worth

State/Province

Texas

ZIP/Postal Code

76104

Country

United States

Facility Name

GSK Investigational Site

City

Gonzales

State/Province

Texas

ZIP/Postal Code

78629

Country

United States

Facility Name

GSK Investigational Site

City

Houston

State/Province

Texas

ZIP/Postal Code

77030

Country

United States

Facility Name

GSK Investigational Site

City

Houston

State/Province

Texas

ZIP/Postal Code

77034

Country

United States

Facility Name

GSK Investigational Site

City

Houston

State/Province

Texas

ZIP/Postal Code

77043

Country

United States

Facility Name

GSK Investigational Site

City

Katy

State/Province

Texas

ZIP/Postal Code

77450

Country

United States

Facility Name

GSK Investigational Site

City

Kerrville

State/Province

Texas

ZIP/Postal Code

78028

Country

United States

Facility Name

GSK Investigational Site

City

Kingwood

State/Province

Texas

ZIP/Postal Code

77339

Country

United States

Facility Name

GSK Investigational Site

City

Lewisville

State/Province

Texas

ZIP/Postal Code

75067

Country

United States

Facility Name

GSK Investigational Site

City

Longview

State/Province

Texas

ZIP/Postal Code

75605

Country

United States

Facility Name

GSK Investigational Site

City

Plano

State/Province

Texas

ZIP/Postal Code

75093

Country

United States

Facility Name

GSK Investigational Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78215

Country

United States

Facility Name

GSK Investigational Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78229

Country

United States

Facility Name

GSK Investigational Site

City

Sealy

State/Province

Texas

ZIP/Postal Code

77474

Country

United States

Facility Name

GSK Investigational Site

City

Sugar Land

State/Province

Texas

ZIP/Postal Code

77479

Country

United States

Facility Name

GSK Investigational Site

City

Tomball

State/Province

Texas

ZIP/Postal Code

77375

Country

United States

Facility Name

GSK Investigational Site

City

Abingdon

State/Province

Virginia

ZIP/Postal Code

24210

Country

United States

Facility Name

GSK Investigational Site

City

Hampton

State/Province

Virginia

ZIP/Postal Code

23666

Country

United States

Facility Name

GSK Investigational Site

City

Lynchburg

State/Province

Virginia

ZIP/Postal Code

24501

Country

United States

Facility Name

GSK Investigational Site

City

Richmond

State/Province

Virginia

ZIP/Postal Code

23225

Country

United States

Facility Name

GSK Investigational Site

City

Richmond

State/Province

Virginia

ZIP/Postal Code

23229

Country

United States

Facility Name

GSK Investigational Site

City

Richmond

State/Province

Virginia

ZIP/Postal Code

23249

Country

United States

Facility Name

GSK Investigational Site

City

Virginia Beach

State/Province

Virginia

ZIP/Postal Code

23454

Country

United States

Facility Name

GSK Investigational Site

City

Bellingham

State/Province

Washington

ZIP/Postal Code

98225

Country

United States

Facility Name

GSK Investigational Site

City

Everett

State/Province

Washington

ZIP/Postal Code

98208

Country

United States

Facility Name

GSK Investigational Site

City

Renton

State/Province

Washington

ZIP/Postal Code

98055

Country

United States

Facility Name

GSK Investigational Site

City

Renton

State/Province

Washington

ZIP/Postal Code

98057

Country

United States

Facility Name

GSK Investigational Site

City

Seattle

State/Province

Washington

ZIP/Postal Code

98122

Country

United States

Facility Name

GSK Investigational Site

City

Spokane Valley

State/Province

Washington

ZIP/Postal Code

99216

Country

United States

Facility Name

GSK Investigational Site

City

Tacoma

State/Province

Washington

ZIP/Postal Code

98405

Country

United States

Facility Name

GSK Investigational Site

City

Bahía Blanca

State/Province

Buenos Aires

ZIP/Postal Code

B8000AAK

Country

Argentina

Facility Name

GSK Investigational Site

City

Caba

State/Province

Buenos Aires

Country

Argentina

Facility Name

GSK Investigational Site

City

Ciudad Autonoma de Buenos Aires

State/Province

Buenos Aires

ZIP/Postal Code

C1028AAP

Country

Argentina

Facility Name

GSK Investigational Site

City

Ciudad Autonoma de Buenos Aires

State/Province

Buenos Aires

ZIP/Postal Code

C1414AIF

Country

Argentina

Facility Name

GSK Investigational Site

City

Ciudad Autonoma de Buenos Aires

State/Province

Buenos Aires

ZIP/Postal Code

C1425AGC

Country

Argentina

Facility Name

GSK Investigational Site

City

Florida

State/Province

Buenos Aires

ZIP/Postal Code

1602

Country

Argentina

Facility Name

GSK Investigational Site

City

La Plata

State/Province

Buenos Aires

ZIP/Postal Code

1900

Country

Argentina

Facility Name

GSK Investigational Site

City

Mar del Plata

State/Province

Buenos Aires

ZIP/Postal Code

7600

Country

Argentina

Facility Name

GSK Investigational Site

City

Mar del Plata

State/Province

Buenos Aires

ZIP/Postal Code

B7600FZN

Country

Argentina

Facility Name

GSK Investigational Site

City

Nueve de Julio

State/Province

Buenos Aires

ZIP/Postal Code

B6500BWQ

Country

Argentina

Facility Name

GSK Investigational Site

City

Paraná

State/Province

Buenos Aires

ZIP/Postal Code

E3100BHK

Country

Argentina

Facility Name

GSK Investigational Site

City

Vicente Lopez

State/Province

Buenos Aires

ZIP/Postal Code

B1602DOH

Country

Argentina

Facility Name

GSK Investigational Site

City

Cordoba

State/Province

Córdova

ZIP/Postal Code

X5003DCE

Country

Argentina

Facility Name

GSK Investigational Site

City

Concepcion del Uruguay

State/Province

Entre Ríos

ZIP/Postal Code

3260

Country

Argentina

Facility Name

GSK Investigational Site

City

San Rafael

State/Province

Mendoza

ZIP/Postal Code

5600

Country

Argentina

Facility Name

GSK Investigational Site

City

Rosario

State/Province

Santa Fe

ZIP/Postal Code

2000

Country

Argentina

Facility Name

GSK Investigational Site

City

Rosario

State/Province

Santa Fe

ZIP/Postal Code

S2002OJN

Country

Argentina

Facility Name

GSK Investigational Site

City

San Miguel de Tucuman

State/Province

Tucumán

ZIP/Postal Code

4000

Country

Argentina

Facility Name

GSK Investigational Site

City

Berazategui, Buenos Aires

ZIP/Postal Code

B1884AAC

Country

Argentina

Facility Name

GSK Investigational Site

City

Berazategui

ZIP/Postal Code

1886

Country

Argentina

Facility Name

GSK Investigational Site

City

Buenos Aires

ZIP/Postal Code

C1120AAC

Country

Argentina

Facility Name

GSK Investigational Site

City

Buenos Aires

ZIP/Postal Code

C1424BSF

Country

Argentina

Facility Name

GSK Investigational Site

City

Buenos Aires

ZIP/Postal Code

C1425BEN

Country

Argentina

Facility Name

GSK Investigational Site

City

Capital Federal

ZIP/Postal Code

C1440BRR

Country

Argentina

Facility Name

GSK Investigational Site

City

Ciudad Autonoma de Buenis Aires

ZIP/Postal Code

C1015ABR

Country

Argentina

Facility Name

GSK Investigational Site

City

Ciudad Autónoma de Buenos Aires

ZIP/Postal Code

C1121ABE

Country

Argentina

Facility Name

GSK Investigational Site

City

Ciudad Autónoma de Buenos Aires

ZIP/Postal Code

C1128AAF

Country

Argentina

Facility Name

GSK Investigational Site

City

Ciudad Autónoma de Buenos Aires

ZIP/Postal Code

C1426ABP

Country

Argentina

Facility Name

GSK Investigational Site

City

Cordoba

ZIP/Postal Code

5000

Country

Argentina

Facility Name

GSK Investigational Site

City

Coronel Suarez

ZIP/Postal Code

7540

Country

Argentina

Facility Name

GSK Investigational Site

City

Mendoza

ZIP/Postal Code

5500

Country

Argentina

Facility Name

GSK Investigational Site

City

Mendoza

ZIP/Postal Code

M5500CCG

Country

Argentina

Facility Name

GSK Investigational Site

City

Monte Grande

ZIP/Postal Code

1842

Country

Argentina

Facility Name

GSK Investigational Site

City

Salta

ZIP/Postal Code

A4400ERH

Country

Argentina

Facility Name

GSK Investigational Site

City

San Miguel de Tucumán

ZIP/Postal Code

4000

Country

Argentina

Facility Name

GSK Investigational Site

City

Santa Fe

ZIP/Postal Code

3000

Country

Argentina

Facility Name

GSK Investigational Site

City

Santa Rosa

ZIP/Postal Code

6300

Country

Argentina

Facility Name

GSK Investigational Site

City

Concord

State/Province

New South Wales

ZIP/Postal Code

2139

Country

Australia

Facility Name

GSK Investigational Site

City

Gosford

State/Province

New South Wales

ZIP/Postal Code

2250

Country

Australia

Facility Name

GSK Investigational Site

City

Maroubra

State/Province

New South Wales

ZIP/Postal Code

2035

Country

Australia

Facility Name

GSK Investigational Site

City

Westmead

State/Province

New South Wales

ZIP/Postal Code

2145

Country

Australia

Facility Name

GSK Investigational Site

City

Cairns

State/Province

Queensland

ZIP/Postal Code

4870

Country

Australia

Facility Name

GSK Investigational Site

City

Carina Heights

State/Province

Queensland

ZIP/Postal Code

4152

Country

Australia

Facility Name

GSK Investigational Site

City

Adelaide

State/Province

South Australia

ZIP/Postal Code

5000

Country

Australia

Facility Name

GSK Investigational Site

City

Daw Park

State/Province

South Australia

ZIP/Postal Code

5041

Country

Australia

Facility Name

GSK Investigational Site

City

Clayton

State/Province

Victoria

ZIP/Postal Code

3168

Country

Australia

Facility Name

GSK Investigational Site

City

Footscray

State/Province

Victoria

ZIP/Postal Code

3011

Country

Australia

Facility Name

GSK Investigational Site

City

Frankston

State/Province

Victoria

ZIP/Postal Code

3199

Country

Australia

Facility Name

GSK Investigational Site

City

Geelong

State/Province

Victoria

ZIP/Postal Code

3220

Country

Australia

Facility Name

GSK Investigational Site

City

Hamilton

State/Province

Victoria

ZIP/Postal Code

3300

Country

Australia

Facility Name

GSK Investigational Site

City

Murdoch

State/Province

Western Australia

ZIP/Postal Code

6964

Country

Australia

Facility Name

GSK Investigational Site

City

Nedlands

State/Province

Western Australia

ZIP/Postal Code

6009

Country

Australia

Facility Name

GSK Investigational Site

City

Liverpool

ZIP/Postal Code

2107

Country

Australia

Facility Name

GSK Investigational Site

City

Feldbach

ZIP/Postal Code

8330

Country

Austria

Facility Name

GSK Investigational Site

City

Feldkirch

ZIP/Postal Code

6800

Country

Austria

Facility Name

GSK Investigational Site

City

Grieskirchen

ZIP/Postal Code

A-4710

Country

Austria

Facility Name

GSK Investigational Site

City

Thalheim bei Wels

ZIP/Postal Code

4600

Country

Austria

Facility Name

GSK Investigational Site

City

Vienna

ZIP/Postal Code

A-1030

Country

Austria

Facility Name

GSK Investigational Site

City

Antwerpen

ZIP/Postal Code

2060

Country

Belgium

Facility Name

GSK Investigational Site

City

Brugge

ZIP/Postal Code

8000

Country

Belgium

Facility Name

GSK Investigational Site

City

Brussels

ZIP/Postal Code

1200

Country

Belgium

Facility Name

GSK Investigational Site

City

Erpent

ZIP/Postal Code

5101

Country

Belgium

Facility Name

GSK Investigational Site

City

Genk

ZIP/Postal Code

3600

Country

Belgium

Facility Name

GSK Investigational Site

City

Gent

ZIP/Postal Code

9000

Country

Belgium

Facility Name

GSK Investigational Site

City

Gilly

ZIP/Postal Code

6060

Country

Belgium

Facility Name

GSK Investigational Site

City

Hasselt

ZIP/Postal Code

3500

Country

Belgium

Facility Name

GSK Investigational Site

City

Liège

ZIP/Postal Code

4000

Country

Belgium

Facility Name

GSK Investigational Site

City

Malmedy

ZIP/Postal Code

4960

Country

Belgium

Facility Name

GSK Investigational Site

City

Mechelen

ZIP/Postal Code

2800

Country

Belgium

Facility Name

GSK Investigational Site

City

Montigny-Le-Tilleul

ZIP/Postal Code

6110

Country

Belgium

Facility Name

GSK Investigational Site

City

Oostende

ZIP/Postal Code

8400

Country

Belgium

Facility Name

GSK Investigational Site

City

Roeselaere

ZIP/Postal Code

8800

Country

Belgium

Facility Name

GSK Investigational Site

City

Turnhout

ZIP/Postal Code

2300

Country

Belgium

Facility Name

GSK Investigational Site

City

Recife

State/Province

Pernambuco

ZIP/Postal Code

50920-900

Country

Brazil

Facility Name

GSK Investigational Site

City

Porto Alegre

State/Province

Rio Grande Do Sul

ZIP/Postal Code

90035-074

Country

Brazil

Facility Name

GSK Investigational Site

City

Porto Alegre

State/Province

Rio Grande Do Sul

ZIP/Postal Code

90480-000

Country

Brazil

Facility Name

GSK Investigational Site

City

Porto Alegre

State/Province

Rio Grande Do Sul

ZIP/Postal Code

90610000

Country

Brazil

Facility Name

GSK Investigational Site

City

Blumenau

State/Province

Santa Catarina

ZIP/Postal Code

89030-101

Country

Brazil

Facility Name

GSK Investigational Site

City

Florianopolis

State/Province

Santa Catarina

ZIP/Postal Code

88040-970

Country

Brazil

Facility Name

GSK Investigational Site

City

Rio de Janeiro

ZIP/Postal Code

21941-913

Country

Brazil

Facility Name

GSK Investigational Site

City

São Paulo

ZIP/Postal Code

01323903

Country

Brazil

Facility Name

GSK Investigational Site

City

São Paulo

ZIP/Postal Code

04023900

Country

Brazil

Facility Name

GSK Investigational Site

City

São Paulo

ZIP/Postal Code

04266-010

Country

Brazil

Facility Name

GSK Investigational Site

City

São Paulo

ZIP/Postal Code

05403-000

Country

Brazil

Facility Name

GSK Investigational Site

City

Edmonton

State/Province

Alberta

ZIP/Postal Code

T6G 2G3

Country

Canada

Facility Name

GSK Investigational Site

City

Sherwood Park

State/Province

Alberta

ZIP/Postal Code

T8H 0N2

Country

Canada

Facility Name

GSK Investigational Site

City

Winnipeg

State/Province

Manitoba

ZIP/Postal Code

R2H 2A6

Country

Canada

Facility Name

GSK Investigational Site

City

Winnipeg

State/Province

Manitoba

ZIP/Postal Code

R2K 3S8

Country

Canada

Facility Name

GSK Investigational Site

City

Moncton

State/Province

New Brunswick

ZIP/Postal Code

E1G 2K5

Country

Canada

Facility Name

GSK Investigational Site

City

Truro

State/Province

Nova Scotia

ZIP/Postal Code

B2N 1L2

Country

Canada

Facility Name

GSK Investigational Site

City

Burlington

State/Province

Ontario

ZIP/Postal Code

L7N 3V2

Country

Canada

Facility Name

GSK Investigational Site

City

Cornwall

State/Province

Ontario

ZIP/Postal Code

K6H4M4

Country

Canada

Facility Name

GSK Investigational Site

City

Hamilton

State/Province

Ontario

ZIP/Postal Code

L8L 5G8

Country

Canada

Facility Name

GSK Investigational Site

City

Hamilton

State/Province

Ontario

ZIP/Postal Code

L8N 3Z5

Country

Canada

Facility Name

GSK Investigational Site

City

Sarnia

State/Province

Ontario

ZIP/Postal Code

N7T 4X3

Country

Canada

Facility Name

GSK Investigational Site

City

Sudbury

State/Province

Ontario

ZIP/Postal Code

P3A 1Y8

Country

Canada

Facility Name

GSK Investigational Site

City

Sudbury

State/Province

Ontario

ZIP/Postal Code

P3E 1H5

Country

Canada

Facility Name

GSK Investigational Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M3J 2C5

Country

Canada

Facility Name

GSK Investigational Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M4S 1Y2

Country

Canada

Facility Name

GSK Investigational Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M5T 3A9

Country

Canada

Facility Name

GSK Investigational Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M9C 4Z5

Country

Canada

Facility Name

GSK Investigational Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M9W 4L6

Country

Canada

Facility Name

GSK Investigational Site

City

Windsor

State/Province

Ontario

ZIP/Postal Code

N8X 5A6

Country

Canada

Facility Name

GSK Investigational Site

City

Gatineau

State/Province

Quebec

ZIP/Postal Code

J8Y 6S8

Country

Canada

Facility Name

GSK Investigational Site

City

Mirabel

State/Province

Quebec

ZIP/Postal Code

J7J 2K8

Country

Canada

Facility Name

GSK Investigational Site

City

Montréal

State/Province

Quebec

ZIP/Postal Code

H1M 1B1

Country

Canada

Facility Name

GSK Investigational Site

City

St-Charles-Borromée

State/Province

Quebec

ZIP/Postal Code

J6E 2B4

Country

Canada

Facility Name

GSK Investigational Site

City

Trois Rivieres

State/Province

Quebec

ZIP/Postal Code

G8T 7A1

Country

Canada

Facility Name

GSK Investigational Site

City

Quebec

ZIP/Postal Code

G1V 4G5

Country

Canada

Facility Name

GSK Investigational Site

City

Quebec

ZIP/Postal Code

G3K 2P8

Country

Canada

Facility Name

GSK Investigational Site

City

Concepción

State/Province

Región Del Biobio

ZIP/Postal Code

4070038

Country

Chile

Facility Name

GSK Investigational Site

City

Curicó

State/Province

Región Del Maule

ZIP/Postal Code

3341643

Country

Chile

Facility Name

GSK Investigational Site

City

Talca

State/Province

Región Del Maule

ZIP/Postal Code

3465584

Country

Chile

Facility Name

GSK Investigational Site

City

Puente Alto - Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

8207257

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

7500692

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

7500710

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

7510186

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

7750495

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

7860406

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

8360160

Country

Chile

Facility Name

GSK Investigational Site

City

Valparaiso

State/Province

Valparaíso

ZIP/Postal Code

2341131

Country

Chile

Facility Name

GSK Investigational Site

City

Viña del Mar

State/Province

Valparaíso

ZIP/Postal Code

2520024

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

ZIP/Postal Code

7500698

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

ZIP/Postal Code

8380453

Country

Chile

Facility Name

GSK Investigational Site

City

Talcahuano

ZIP/Postal Code

4270918

Country

Chile

Facility Name

GSK Investigational Site

City

Viña del Mar

ZIP/Postal Code

2520594

Country

Chile

Facility Name

GSK Investigational Site

City

Guangzhou

State/Province

Guangdong

ZIP/Postal Code

510080

Country

China

Facility Name

GSK Investigational Site

City

Guangzhou

State/Province

Guangdong

ZIP/Postal Code

510120

Country

China

Facility Name

GSK Investigational Site

City

Guangzhou

State/Province

Guangdong

ZIP/Postal Code

510150

Country

China

Facility Name

GSK Investigational Site

City

Guangzhou

State/Province

Guangdong

ZIP/Postal Code

510180

Country

China

Facility Name

GSK Investigational Site

City

Guangzhou

State/Province

Guangdong

ZIP/Postal Code

510630

Country

China

Facility Name

GSK Investigational Site

City

Zhanjiang

State/Province

Guangdong

ZIP/Postal Code

524001

Country

China

Facility Name

GSK Investigational Site

City

Nanning

State/Province

Guangxi

ZIP/Postal Code

530021

Country

China

Facility Name

GSK Investigational Site

City

Haikou

State/Province

Hainan

ZIP/Postal Code

570311

Country

China

Facility Name

GSK Investigational Site

City

Shijiazhuang

State/Province

Hebei

ZIP/Postal Code

050000

Country

China

Facility Name

GSK Investigational Site

City

Nanjing

State/Province

Jiangsu

ZIP/Postal Code

210006

Country

China

Facility Name

GSK Investigational Site

City

Nanjing

State/Province

Jiangsu

ZIP/Postal Code

210008

Country

China

Facility Name

GSK Investigational Site

City

Nanjing

State/Province

Jiangsu

ZIP/Postal Code

210029

Country

China

Facility Name

GSK Investigational Site

City

Nanchang

State/Province

Jiangxi

ZIP/Postal Code

330006

Country

China

Facility Name

GSK Investigational Site

City

Changchun

State/Province

Jilin

ZIP/Postal Code

130041

Country

China

Facility Name

GSK Investigational Site

City

Shenyang

State/Province

Liaoning

ZIP/Postal Code

110004

Country

China

Facility Name

GSK Investigational Site

City

Shenyang

State/Province

Liaoning

ZIP/Postal Code

110015

Country

China

Facility Name

GSK Investigational Site

City

Yinchuan

State/Province

Ningxia

ZIP/Postal Code

750004

Country

China

Facility Name

GSK Investigational Site

City

Jinan

State/Province

Shandong

ZIP/Postal Code

250012

Country

China

Facility Name

GSK Investigational Site

City

Jinan

State/Province

Shandong

ZIP/Postal Code

250013

Country

China

Facility Name

GSK Investigational Site

City

Qingdao

State/Province

Shandong

ZIP/Postal Code

266071

Country

China

Facility Name

GSK Investigational Site

City

Taiyuan

State/Province

Shanxi

ZIP/Postal Code

030001

Country

China

Facility Name

GSK Investigational Site

City

Xian

State/Province

Shanxi

ZIP/Postal Code

710032

Country

China

Facility Name

GSK Investigational Site

City

Chengdu

State/Province

Sichuan

ZIP/Postal Code

610041

Country

China

Facility Name

GSK Investigational Site

City

Hangzhou

State/Province

Zhejiang

Country

China

Facility Name

GSK Investigational Site

City

Beijing

ZIP/Postal Code

100020

Country

China

Facility Name

GSK Investigational Site

City

Beijing

ZIP/Postal Code

100029

Country

China

Facility Name

GSK Investigational Site

City

Beijing

ZIP/Postal Code

100034

Country

China

Facility Name

GSK Investigational Site

City

Beijing

ZIP/Postal Code

100050

Country

China

Facility Name

GSK Investigational Site

City

Beijing

ZIP/Postal Code

100191

Country

China

Facility Name

GSK Investigational Site

City

Changsha

ZIP/Postal Code

410013

Country

China

Facility Name

GSK Investigational Site

City

Chongqing

ZIP/Postal Code

400037

Country

China

Facility Name

GSK Investigational Site

City

Chongqing

ZIP/Postal Code

400038

Country

China

Facility Name

GSK Investigational Site

City

Chongqing

Country

China

Facility Name

GSK Investigational Site

City

Fuzhou

ZIP/Postal Code

350025

Country

China

Facility Name

GSK Investigational Site

City

Guangzhou

ZIP/Postal Code

510080

Country

China

Facility Name

GSK Investigational Site

City

Nanchang

ZIP/Postal Code

330006

Country

China

Facility Name

GSK Investigational Site

City

Shanghai

ZIP/Postal Code

200025

Country

China

Facility Name

GSK Investigational Site

City

Shanghai

ZIP/Postal Code

200433

Country

China

Facility Name

GSK Investigational Site

City

Tianjin

ZIP/Postal Code

300052

Country

China

Facility Name

GSK Investigational Site

City

Wuxi

ZIP/Postal Code

214023

Country

China

Facility Name

GSK Investigational Site

City

Barranquilla

Country

Colombia

Facility Name

GSK Investigational Site

City

Bogota

Country

Colombia

Facility Name

GSK Investigational Site

City

Bogotá

ZIP/Postal Code

80CO

Country

Colombia

Facility Name

GSK Investigational Site

City

Bogotá

Country

Colombia

Facility Name

GSK Investigational Site

City

Medellin

Country

Colombia

Facility Name

GSK Investigational Site

City

Benesov

ZIP/Postal Code

256 30

Country

Czechia

Facility Name

GSK Investigational Site

City

Brandys nad Labem

ZIP/Postal Code

250 01

Country

Czechia

Facility Name

GSK Investigational Site

City

Cvikov

ZIP/Postal Code

471 54

Country

Czechia

Facility Name

GSK Investigational Site

City

Holesov

ZIP/Postal Code

769 01

Country

Czechia

Facility Name

GSK Investigational Site

City

Hradec Kralove

ZIP/Postal Code

500 05

Country

Czechia

Facility Name

GSK Investigational Site

City

Jaromer

ZIP/Postal Code

551 01

Country

Czechia

Facility Name

GSK Investigational Site

City

Olomouc

ZIP/Postal Code

772 00

Country

Czechia

Facility Name

GSK Investigational Site

City

Olomouc

ZIP/Postal Code

775 20

Country

Czechia

Facility Name

GSK Investigational Site

City

Ostrava - Poruba

ZIP/Postal Code

70868

Country

Czechia

Facility Name

GSK Investigational Site

City

Plzen

ZIP/Postal Code

301 00

Country

Czechia

Facility Name

GSK Investigational Site

City

Praha 5

ZIP/Postal Code

150 06

Country

Czechia

Facility Name

GSK Investigational Site

City

Praha 8

ZIP/Postal Code

182 00

Country

Czechia

Facility Name

GSK Investigational Site

City

Tabor

ZIP/Postal Code

390 19

Country

Czechia

Facility Name

GSK Investigational Site

City

Teplice

ZIP/Postal Code

415 10

Country

Czechia

Facility Name

GSK Investigational Site

City

Trebic

ZIP/Postal Code

674 01

Country

Czechia

Facility Name

GSK Investigational Site

City

Aalborg

ZIP/Postal Code

9100

Country

Denmark

Facility Name

GSK Investigational Site

City

Aarhus C

ZIP/Postal Code

8000

Country

Denmark

Facility Name

GSK Investigational Site

City

Hellerup

ZIP/Postal Code

2900

Country

Denmark

Facility Name

GSK Investigational Site

City

Hvidovre

ZIP/Postal Code

2650

Country

Denmark

Facility Name

GSK Investigational Site

City

Kolding

ZIP/Postal Code

DK-6000

Country

Denmark

Facility Name

GSK Investigational Site

City

Odense C

ZIP/Postal Code

5000

Country

Denmark

Facility Name

GSK Investigational Site

City

Roskilde

ZIP/Postal Code

4000

Country

Denmark

Facility Name

GSK Investigational Site

City

Sønderborg

ZIP/Postal Code

6400

Country

Denmark

Facility Name

GSK Investigational Site

City

Espoo

ZIP/Postal Code

02740

Country

Finland

Facility Name

GSK Investigational Site

City

Helsinki

ZIP/Postal Code

00290

Country

Finland

Facility Name

GSK Investigational Site

City

Jyvaskyla

ZIP/Postal Code

40100

Country

Finland

Facility Name

GSK Investigational Site

City

Lohja

ZIP/Postal Code

08200

Country

Finland

Facility Name

GSK Investigational Site

City

Tampere

ZIP/Postal Code

33520

Country

Finland

Facility Name

GSK Investigational Site

City

Turku

ZIP/Postal Code

20100

Country

Finland

Facility Name

GSK Investigational Site

City

Turku

ZIP/Postal Code

20520

Country

Finland

Facility Name

GSK Investigational Site

City

Bayonne cedex

ZIP/Postal Code

64109

Country

France

Facility Name

GSK Investigational Site

City

Brest Cedex

ZIP/Postal Code

29609

Country

France

Facility Name

GSK Investigational Site

City

Briis-sous-Forge

ZIP/Postal Code

91640

Country

France

Facility Name

GSK Investigational Site

City

Grenoble cedex 9

ZIP/Postal Code

38043

Country

France

Facility Name

GSK Investigational Site

City

Le Mans

ZIP/Postal Code

72000

Country

France

Facility Name

GSK Investigational Site

City

Lyon cedex 04

ZIP/Postal Code

69317

Country

France

Facility Name

GSK Investigational Site

City

Marseille cedex 03

ZIP/Postal Code

13331

Country

France

Facility Name

GSK Investigational Site

City

Montauban cedex

ZIP/Postal Code

82017

Country

France

Facility Name

GSK Investigational Site

City

Montpellier cedex 5

ZIP/Postal Code

34295

Country

France

Facility Name

GSK Investigational Site

City

Nimes

ZIP/Postal Code

30900

Country

France

Facility Name

GSK Investigational Site

City

Orléans cedex 2

ZIP/Postal Code

45067

Country

France

Facility Name

GSK Investigational Site

City

Paris

ZIP/Postal Code

75014

Country

France

Facility Name

GSK Investigational Site

City

Perpignan

ZIP/Postal Code

66000

Country

France

Facility Name

GSK Investigational Site

City

Pessac cedex

ZIP/Postal Code

33604

Country

France

Facility Name

GSK Investigational Site

City

Pringy cedex

ZIP/Postal Code

74374

Country

France

Facility Name

GSK Investigational Site

City

Rennes Cedex 9

ZIP/Postal Code

35033

Country

France

Facility Name

GSK Investigational Site

City

Strasbourg cedex

ZIP/Postal Code

67091

Country

France

Facility Name

GSK Investigational Site

City

Toulon

ZIP/Postal Code

83000

Country

France

Facility Name

GSK Investigational Site

City

Vandoeuvre-les-Nancy

ZIP/Postal Code

54511

Country

France

Facility Name

GSK Investigational Site

City

Deggingen

State/Province

Baden-Wuerttemberg

ZIP/Postal Code

73326

Country

Germany

Facility Name

GSK Investigational Site

City

Leonberg

State/Province

Baden-Wuerttemberg

ZIP/Postal Code

71229

Country

Germany

Facility Name

GSK Investigational Site

City

Mannheim

State/Province

Baden-Wuerttemberg

ZIP/Postal Code

68161

Country

Germany

Facility Name

GSK Investigational Site

City

Mannheim

State/Province

Baden-Wuerttemberg

ZIP/Postal Code

68167

Country

Germany

Facility Name

GSK Investigational Site

City

Stuttgart

State/Province

Baden-Wuerttemberg

ZIP/Postal Code

70372

Country

Germany

Facility Name

GSK Investigational Site

City

Stuttgart

State/Province

Baden-Wuerttemberg

ZIP/Postal Code

70378

Country

Germany

Facility Name

GSK Investigational Site

City

Wiesloch

State/Province

Baden-Wuerttemberg

ZIP/Postal Code

69168

Country

Germany

Facility Name

GSK Investigational Site

City

Aschaffenburg

State/Province

Bayern

ZIP/Postal Code

63739

Country

Germany

Facility Name

GSK Investigational Site

City

Augsburg

State/Province

Bayern

ZIP/Postal Code

86150

Country

Germany

Facility Name

GSK Investigational Site

City

Bad Woerrishofen

State/Province

Bayern

ZIP/Postal Code

86825

Country

Germany

Facility Name

GSK Investigational Site

City

Bamberg

State/Province

Bayern

ZIP/Postal Code

96049

Country

Germany

Facility Name

GSK Investigational Site

City

Dachau

State/Province

Bayern

ZIP/Postal Code

85221

Country

Germany

Facility Name

GSK Investigational Site

City

Dillingen

State/Province

Bayern

ZIP/Postal Code

89407

Country

Germany

Facility Name

GSK Investigational Site

City

Donaustauf

State/Province

Bayern

ZIP/Postal Code

93093

Country

Germany

Facility Name

GSK Investigational Site

City

Garmisch-Partenirchen

State/Province

Bayern

ZIP/Postal Code

82467

Country

Germany

Facility Name

GSK Investigational Site

City

Gauting

State/Province

Bayern

ZIP/Postal Code

82131

Country

Germany

Facility Name

GSK Investigational Site

City

Landsberg

State/Province

Bayern

ZIP/Postal Code

86899

Country

Germany

Facility Name

GSK Investigational Site

City

Muenchen

State/Province

Bayern

ZIP/Postal Code

80339

Country

Germany

Facility Name

GSK Investigational Site

City

Muenchen

State/Province

Bayern

ZIP/Postal Code

80539

Country

Germany

Facility Name

GSK Investigational Site

City

Neu-Ulm

State/Province

Bayern

ZIP/Postal Code

89231

Country

Germany

Facility Name

GSK Investigational Site

City

Nuernberg

State/Province

Bayern

ZIP/Postal Code

90402

Country

Germany

Facility Name

GSK Investigational Site

City

Rosenheim

State/Province

Bayern

ZIP/Postal Code

83022

Country

Germany

Facility Name

GSK Investigational Site

City

Wallerfing

State/Province

Bayern

ZIP/Postal Code

94574

Country

Germany

Facility Name

GSK Investigational Site

City

Cottbus

State/Province

Brandenburg

ZIP/Postal Code

03050

Country

Germany

Facility Name

GSK Investigational Site

City

Potsdam

State/Province

Brandenburg

ZIP/Postal Code

14467

Country

Germany

Facility Name

GSK Investigational Site

City

Potsdam

State/Province

Brandenburg

ZIP/Postal Code

14469

Country

Germany

Facility Name

GSK Investigational Site

City

Rathenow

State/Province

Brandenburg

ZIP/Postal Code

14712

Country

Germany

Facility Name

GSK Investigational Site

City

Ruedersdorf

State/Province

Brandenburg

ZIP/Postal Code

15562

Country

Germany

Facility Name

GSK Investigational Site

City

Bensheim

State/Province

Hessen

ZIP/Postal Code

64625

Country

Germany

Facility Name

GSK Investigational Site

City

Frankenberg

State/Province

Hessen

ZIP/Postal Code

35066

Country

Germany

Facility Name

GSK Investigational Site

City

Frankfurt

State/Province

Hessen

ZIP/Postal Code

60389

Country

Germany

Facility Name

GSK Investigational Site

City

Frankfurt

State/Province

Hessen

ZIP/Postal Code

60596

Country

Germany

Facility Name

GSK Investigational Site

City

Fuldatal

State/Province

Hessen

ZIP/Postal Code

34233

Country

Germany

Facility Name

GSK Investigational Site

City

Fulda

State/Province

Hessen

ZIP/Postal Code

36039

Country

Germany

Facility Name

GSK Investigational Site

City

Kassel

State/Province

Hessen

ZIP/Postal Code

34121

Country

Germany

Facility Name

GSK Investigational Site

City

Marburg

State/Province

Hessen

ZIP/Postal Code

35037

Country

Germany

Facility Name

GSK Investigational Site

City

Neu isenburg

State/Province

Hessen

ZIP/Postal Code

63263

Country

Germany

Facility Name

GSK Investigational Site

City

Offenbach

State/Province

Hessen

ZIP/Postal Code

63071

Country

Germany

Facility Name

GSK Investigational Site

City

Rodgau

State/Province

Hessen

ZIP/Postal Code

63110

Country

Germany

Facility Name

GSK Investigational Site

City

Ruesselsheim

State/Province

Hessen

ZIP/Postal Code

65428

Country

Germany

Facility Name

GSK Investigational Site

City

Hannover

State/Province

Niedersachsen

ZIP/Postal Code

30167

Country

Germany

Facility Name

GSK Investigational Site

City

Hannover

State/Province

Niedersachsen

ZIP/Postal Code

30173

Country

Germany

Facility Name

GSK Investigational Site

City

Peine

State/Province

Niedersachsen

ZIP/Postal Code

31224

Country

Germany

Facility Name

GSK Investigational Site

City

Wardenburg

State/Province

Niedersachsen

ZIP/Postal Code

26203

Country

Germany

Facility Name

GSK Investigational Site

City

Bad Lippspringe

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

33175

Country

Germany

Facility Name

GSK Investigational Site

City

Bergisch Gladbach

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

51429

Country

Germany

Facility Name

GSK Investigational Site

City

Bonn

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

53119

Country

Germany

Facility Name

GSK Investigational Site

City

Bonn

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

53123

Country

Germany

Facility Name

GSK Investigational Site

City

Dortmund

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

44263

Country

Germany

Facility Name

GSK Investigational Site

City

Dueren

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

52349

Country

Germany

Facility Name

GSK Investigational Site

City

Duisburg

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

47057

Country

Germany

Facility Name

GSK Investigational Site

City

Essen

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

45277

Country

Germany

Facility Name

GSK Investigational Site

City

Essen

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

45355

Country

Germany

Facility Name

GSK Investigational Site

City

Freudenberg

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

57258

Country

Germany

Facility Name

GSK Investigational Site

City

Gelsenkirchen

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

45879

Country

Germany

Facility Name

GSK Investigational Site

City

Gummersbach

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

51643

Country

Germany

Facility Name

GSK Investigational Site

City

Hagen

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

58089

Country

Germany

Facility Name

GSK Investigational Site

City

Kleve

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

47533

Country

Germany

Facility Name

GSK Investigational Site

City

Koeln

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

51065

Country

Germany

Facility Name

GSK Investigational Site

City

Neuss

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

41462

Country

Germany

Facility Name

GSK Investigational Site

City

Ratingen

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

40878

Country

Germany

Facility Name

GSK Investigational Site

City

Rheine

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

48431

Country

Germany

Facility Name

GSK Investigational Site

City

Solingen

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

42699

Country

Germany

Facility Name

GSK Investigational Site

City

Warendorf

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

48231

Country

Germany

Facility Name

GSK Investigational Site

City

Witten

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

58452

Country

Germany

Facility Name

GSK Investigational Site

City

Bernkastel-Kues

State/Province

Rheinland-Pfalz

ZIP/Postal Code

54470

Country

Germany

Facility Name

GSK Investigational Site

City

Koblenz

State/Province

Rheinland-Pfalz

ZIP/Postal Code

56068

Country

Germany

Facility Name

GSK Investigational Site

City

Mainz

State/Province

Rheinland-Pfalz

ZIP/Postal Code

55116

Country

Germany

Facility Name

GSK Investigational Site

City

Neuwied

State/Province

Rheinland-Pfalz

ZIP/Postal Code

56564

Country

Germany

Facility Name

GSK Investigational Site

City

Wissen

State/Province

Rheinland-Pfalz

ZIP/Postal Code

57537

Country

Germany

Facility Name

GSK Investigational Site

City

Saarbruecken

State/Province

Saarland

ZIP/Postal Code

66111

Country

Germany

Facility Name

GSK Investigational Site

City

Halberstadt

State/Province

Sachsen-Anhalt

ZIP/Postal Code

38820

Country

Germany

Facility Name

GSK Investigational Site

City

Halle

State/Province

Sachsen-Anhalt

ZIP/Postal Code

06108

Country

Germany

Facility Name

GSK Investigational Site

City

Hettstedt

State/Province

Sachsen-Anhalt

ZIP/Postal Code

06333

Country

Germany

Facility Name

GSK Investigational Site

City

Teuchern

State/Province

Sachsen-Anhalt

ZIP/Postal Code

06682

Country

Germany

Facility Name

GSK Investigational Site

City

Zerbst

State/Province

Sachsen-Anhalt

ZIP/Postal Code

39261

Country

Germany

Facility Name

GSK Investigational Site

City

Auerbach

State/Province

Sachsen

ZIP/Postal Code

08209

Country

Germany

Facility Name

GSK Investigational Site

City

Delitzsch

State/Province

Sachsen

ZIP/Postal Code

04509

Country

Germany

Facility Name

GSK Investigational Site

City

Leipzg

State/Province

Sachsen

ZIP/Postal Code

04109

Country

Germany

Facility Name

GSK Investigational Site

City

Leipzig

State/Province

Sachsen

ZIP/Postal Code

04103

Country

Germany

Facility Name

GSK Investigational Site

City

Leipzig

State/Province

Sachsen

ZIP/Postal Code

04157

Country

Germany

Facility Name

GSK Investigational Site

City

Leipzig

State/Province

Sachsen

ZIP/Postal Code

04275

Country

Germany

Facility Name

GSK Investigational Site

City

Leipzig

State/Province

Sachsen

ZIP/Postal Code

04357

Country

Germany

Facility Name

GSK Investigational Site

City

Geesthacht

State/Province

Schleswig-Holstein

ZIP/Postal Code

21502

Country

Germany

Facility Name

GSK Investigational Site

City

Luebeck

State/Province

Schleswig-Holstein

ZIP/Postal Code

23558

Country

Germany

Facility Name

GSK Investigational Site

City

Reinfeld

State/Province

Schleswig-Holstein

ZIP/Postal Code

23858

Country

Germany

Facility Name

GSK Investigational Site

City

Schleswig

State/Province

Schleswig-Holstein

ZIP/Postal Code

24837

Country

Germany

Facility Name

GSK Investigational Site

City

Gera

State/Province

Thueringen

ZIP/Postal Code

07548

Country

Germany

Facility Name

GSK Investigational Site

City

Saalfeld

State/Province

Thueringen

ZIP/Postal Code

07318

Country

Germany

Facility Name

GSK Investigational Site

City

Schmoelln

State/Province

Thueringen

ZIP/Postal Code

04626

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

10119

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

10247

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

10367

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

10625

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

10717

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

10961

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

10969

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

12043

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

12157

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

12159

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

12203

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

12627

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13057

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13086

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13156

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13187

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13353

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13507

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13581

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

14059

Country

Germany

Facility Name

GSK Investigational Site

City

Deggendorf

ZIP/Postal Code

94469

Country

Germany

Facility Name

GSK Investigational Site

City

Hamburg

ZIP/Postal Code

22291

Country

Germany

Facility Name

GSK Investigational Site

City

Hamburg

ZIP/Postal Code

22299

Country

Germany

Facility Name

GSK Investigational Site

City

Hamburg

ZIP/Postal Code

22763

Country

Germany

Facility Name

GSK Investigational Site

City

Witten

ZIP/Postal Code

58452

Country

Germany

Facility Name

GSK Investigational Site

City

Kwun Tong

Country

Hong Kong

Facility Name

GSK Investigational Site

City

Lai Chi Kok

Country

Hong Kong

Facility Name

GSK Investigational Site

City

Pokfulam

Country

Hong Kong

Facility Name

GSK Investigational Site

City

Shatin

Country

Hong Kong

Facility Name

GSK Investigational Site

City

Tuen Mun

Country

Hong Kong

Facility Name

GSK Investigational Site

City

Afula

ZIP/Postal Code

18101

Country

Israel

Facility Name

GSK Investigational Site

City

Ashkelon

ZIP/Postal Code

78278

Country

Israel

Facility Name

GSK Investigational Site

City

Haifa

ZIP/Postal Code

34362

Country

Israel

Facility Name

GSK Investigational Site

City

Holon

ZIP/Postal Code

58100

Country

Israel

Facility Name

GSK Investigational Site

City

Jerusalem

ZIP/Postal Code

91031

Country

Israel

Facility Name

GSK Investigational Site

City

Jerusalem

ZIP/Postal Code

91120

Country

Israel

Facility Name

GSK Investigational Site

City

Kfar-Saba

ZIP/Postal Code

44281

Country

Israel

Facility Name

GSK Investigational Site

City

Petah Tikva

ZIP/Postal Code

49100

Country

Israel

Facility Name

GSK Investigational Site

City

Ramat Gan

ZIP/Postal Code

52621

Country

Israel

Facility Name

GSK Investigational Site

City

Rehovot

ZIP/Postal Code

76100

Country

Israel

Facility Name

GSK Investigational Site

City

Tel Aviv

ZIP/Postal Code

67891

Country

Israel

Facility Name

GSK Investigational Site

City

Tel-Aviv

ZIP/Postal Code

64239

Country

Israel

Facility Name

GSK Investigational Site

City

Zrifin

ZIP/Postal Code

70300

Country

Israel

Facility Name

GSK Investigational Site

City

Aichi

ZIP/Postal Code

455-8530

Country

Japan

Facility Name

GSK Investigational Site

City

Aichi

ZIP/Postal Code

457-8510

Country

Japan

Facility Name

GSK Investigational Site

City

Aichi

ZIP/Postal Code

457-8511

Country

Japan

Facility Name

GSK Investigational Site

City

Aichi

ZIP/Postal Code

460-0001

Country

Japan

Facility Name

GSK Investigational Site

City

Aichi

ZIP/Postal Code

471-8513

Country

Japan

Facility Name

GSK Investigational Site

City

Aichi

ZIP/Postal Code

485-0041

Country

Japan

Facility Name

GSK Investigational Site

City

Aichi

ZIP/Postal Code

489-8642

Country

Japan

Facility Name

GSK Investigational Site

City

Chiba

ZIP/Postal Code

278-0004

Country

Japan

Facility Name

GSK Investigational Site

City

Chiba

ZIP/Postal Code

296-8602

Country

Japan

Facility Name

GSK Investigational Site

City

Ehime

ZIP/Postal Code

791-0281

Country

Japan

Facility Name

GSK Investigational Site

City

Fukuoka

ZIP/Postal Code

802-0052

Country

Japan

Facility Name

GSK Investigational Site

City

Fukuoka

ZIP/Postal Code

802-0083

Country

Japan

Facility Name

GSK Investigational Site

City

Fukuoka

ZIP/Postal Code

811-1394

Country

Japan

Facility Name

GSK Investigational Site

City

Fukuoka

ZIP/Postal Code

816-0813

Country

Japan

Facility Name

GSK Investigational Site

City

Fukuoka

ZIP/Postal Code

820-8505

Country

Japan

Facility Name

GSK Investigational Site

City

Fukuoka

ZIP/Postal Code

832-0059

Country

Japan

Facility Name

GSK Investigational Site

City

Gifu

ZIP/Postal Code

500-8717

Country

Japan

Facility Name

GSK Investigational Site

City

Gifu

ZIP/Postal Code

506-8550

Country

Japan

Facility Name

GSK Investigational Site

City

Gifu

ZIP/Postal Code

509-6134

Country

Japan

Facility Name

GSK Investigational Site

City

Gunma

ZIP/Postal Code

372-0831

Country

Japan

Facility Name

GSK Investigational Site

City

Gunma

ZIP/Postal Code

373-0807

Country

Japan

Facility Name

GSK Investigational Site

City

Hiroshima

ZIP/Postal Code

722-8503

Country

Japan

Facility Name

GSK Investigational Site

City

Hiroshima

ZIP/Postal Code

734-8530

Country

Japan

Facility Name

GSK Investigational Site

City

Hiroshima

ZIP/Postal Code

735-8585

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

001-0901

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

053-8506

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

060-0033

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

062-8618

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

063-0005

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

064-0801

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

064-0915

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

070-8644

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

071-8132

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

078-8211

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

080-0805

Country

Japan

Facility Name

GSK Investigational Site

City

Hyogo

ZIP/Postal Code

650-0047

Country

Japan

Facility Name

GSK Investigational Site

City

Hyogo

ZIP/Postal Code

651-0072

Country

Japan

Facility Name

GSK Investigational Site

City

Hyogo

ZIP/Postal Code

653-0013

Country

Japan

Facility Name

GSK Investigational Site

City

Hyogo

ZIP/Postal Code

664-8540

Country

Japan

Facility Name

GSK Investigational Site

City

Hyogo

ZIP/Postal Code

670-0849

Country

Japan

Facility Name

GSK Investigational Site

City

Hyogo

ZIP/Postal Code

672-8064

Country

Japan

Facility Name

GSK Investigational Site

City

Hyogo

ZIP/Postal Code

674-0063

Country

Japan

Facility Name

GSK Investigational Site

City

Hyogo

ZIP/Postal Code

675-8611

Country

Japan

Facility Name

GSK Investigational Site

City

Ibaraki

ZIP/Postal Code

302-0022

Country

Japan

Facility Name

GSK Investigational Site

City

Ibaraki

ZIP/Postal Code

310-0015

Country

Japan

Facility Name

GSK Investigational Site

City

Ibaraki

ZIP/Postal Code

311-3193

Country

Japan

Facility Name

GSK Investigational Site

City

Ibaraki

ZIP/Postal Code

317-0077

Country

Japan

Facility Name

GSK Investigational Site

City

Ibaraki

ZIP/Postal Code

319-1113

Country

Japan

Facility Name

GSK Investigational Site

City

Ishikawa

ZIP/Postal Code

920-8530

Country

Japan

Facility Name

GSK Investigational Site

City

Ishikawa

ZIP/Postal Code

920-8610

Country

Japan

Facility Name

GSK Investigational Site

City

Ishikawa

ZIP/Postal Code

921-8105

Country

Japan

Facility Name

GSK Investigational Site

City

Ishikawa

ZIP/Postal Code

923-8560

Country

Japan

Facility Name

GSK Investigational Site

City

Iwate

ZIP/Postal Code

020-0055

Country

Japan

Facility Name

GSK Investigational Site

City

Kagawa

ZIP/Postal Code

760-0018

Country

Japan

Facility Name

GSK Investigational Site

City

Kagawa

ZIP/Postal Code

760-8538

Country

Japan

Facility Name

GSK Investigational Site

City

Kagawa

ZIP/Postal Code

761-8073

Country

Japan

Facility Name

GSK Investigational Site

City

Kagawa

ZIP/Postal Code

762-8550

Country

Japan

Facility Name

GSK Investigational Site

City

Kanagawa

ZIP/Postal Code

210-0852

Country

Japan

Facility Name

GSK Investigational Site

City

Kanagawa

ZIP/Postal Code

232-0024

Country

Japan

Facility Name

GSK Investigational Site

City

Kanagawa

ZIP/Postal Code

232-0066

Country

Japan

Facility Name

GSK Investigational Site

City

Kanagawa

ZIP/Postal Code

239-0821

Country

Japan

Facility Name

GSK Investigational Site

City

Kanagawa

ZIP/Postal Code

252-5188

Country

Japan

Facility Name

GSK Investigational Site

City

Kanagawa

ZIP/Postal Code

254-8502

Country

Japan

Facility Name

GSK Investigational Site

City

Kochi

ZIP/Postal Code

780-8077

Country

Japan

Facility Name

GSK Investigational Site

City

Kumamoto

ZIP/Postal Code

861-1196

Country

Japan

Facility Name

GSK Investigational Site

City

Kyoto

ZIP/Postal Code

601-1495

Country

Japan

Facility Name

GSK Investigational Site

City

Kyoto

ZIP/Postal Code

607-8062

Country

Japan

Facility Name

GSK Investigational Site

City

Kyoto

ZIP/Postal Code

615-8087

Country

Japan

Facility Name

GSK Investigational Site

City

Mie

ZIP/Postal Code

510-8567

Country

Japan

Facility Name

GSK Investigational Site

City

Mie

ZIP/Postal Code

515-8544

Country

Japan

Facility Name

GSK Investigational Site

City

Miyagi

ZIP/Postal Code

984-8560

Country

Japan

Facility Name

GSK Investigational Site

City

Miyagi

ZIP/Postal Code

985-8506

Country

Japan

Facility Name

GSK Investigational Site

City

Miyagi

ZIP/Postal Code

986-8522

Country

Japan

Facility Name

GSK Investigational Site

City

Miyagi

ZIP/Postal Code

989-1253

Country

Japan

Facility Name

GSK Investigational Site

City

Nagano

ZIP/Postal Code

392-8510

Country

Japan

Facility Name

GSK Investigational Site

City

Niigata

ZIP/Postal Code

940-0856

Country

Japan

Facility Name

GSK Investigational Site

City

Oita

ZIP/Postal Code

870-0921

Country

Japan

Facility Name

GSK Investigational Site

City

Okayama

ZIP/Postal Code

701-0304

Country

Japan

Facility Name

GSK Investigational Site

City

Okayama

ZIP/Postal Code

702-8055

Country

Japan

Facility Name

GSK Investigational Site

City

Okayama

ZIP/Postal Code

711-0921

Country

Japan

Facility Name

GSK Investigational Site

City

Okinawa

ZIP/Postal Code

901-2121

Country

Japan

Facility Name

GSK Investigational Site

City

Okinawa

ZIP/Postal Code

901-2132

Country

Japan

Facility Name

GSK Investigational Site

City

Okinawa

ZIP/Postal Code

901-2393

Country

Japan

Facility Name

GSK Investigational Site

City

Okinawa

ZIP/Postal Code

904-2143

Country

Japan

Facility Name

GSK Investigational Site

City

Okinawa

ZIP/Postal Code

904-2293

Country

Japan

Facility Name

GSK Investigational Site

City

Osaka

ZIP/Postal Code

530-0001

Country

Japan

Facility Name

GSK Investigational Site

City

Osaka

ZIP/Postal Code

533-0024

Country

Japan

Facility Name

GSK Investigational Site

City

Osaka

ZIP/Postal Code

559-0012

Country

Japan

Facility Name

GSK Investigational Site

City

Osaka

ZIP/Postal Code

564-0013

Country

Japan

Facility Name

GSK Investigational Site

City

Osaka

ZIP/Postal Code

576-0016

Country

Japan

Facility Name

GSK Investigational Site

City

Osaka

ZIP/Postal Code

576-0041

Country

Japan

Facility Name

GSK Investigational Site

City

Osaka

ZIP/Postal Code

591-8037

Country

Japan

Facility Name

GSK Investigational Site

City

Osaka

ZIP/Postal Code

591-8555

Country

Japan

Facility Name

GSK Investigational Site

City

Osaka

ZIP/Postal Code

596-8501

Country

Japan

Facility Name

GSK Investigational Site

City

Saitama

ZIP/Postal Code

349-1105

Country

Japan

Facility Name

GSK Investigational Site

City

Shizuoka

ZIP/Postal Code

420-8527

Country

Japan

Facility Name

GSK Investigational Site

City

Shizuoka

ZIP/Postal Code

430-8525

Country

Japan

Facility Name

GSK Investigational Site

City

Tochigi

ZIP/Postal Code

320-0065

Country

Japan

Facility Name

GSK Investigational Site

City

Tokyo

ZIP/Postal Code

103-0027

Country

Japan

Facility Name

GSK Investigational Site

City

Tokyo

ZIP/Postal Code

103-0028

Country

Japan

Facility Name

GSK Investigational Site

City

Tokyo

ZIP/Postal Code

104-8560

Country

Japan

Facility Name

GSK Investigational Site

City

Tokyo

ZIP/Postal Code

120-0033

Country

Japan

Facility Name

GSK Investigational Site

City

Tokyo

ZIP/Postal Code

134-0083

Country

Japan

Facility Name

GSK Investigational Site

City

Tokyo

ZIP/Postal Code

158-8531

Country

Japan

Facility Name

GSK Investigational Site

City

Tokyo

ZIP/Postal Code

194-0023

Country

Japan

Facility Name

GSK Investigational Site

City

Tokyo

ZIP/Postal Code

198-0042

Country

Japan

Facility Name

GSK Investigational Site

City

Tokyo

ZIP/Postal Code

204-8585

Country

Japan

Facility Name

GSK Investigational Site

City

Toyama

ZIP/Postal Code

937-0042

Country

Japan

Facility Name

GSK Investigational Site

City

Toyama

ZIP/Postal Code

938-8502

Country

Japan

Facility Name

GSK Investigational Site

City

Wakayama

ZIP/Postal Code

640-8558

Country

Japan

Facility Name

GSK Investigational Site

City

Yamagata

ZIP/Postal Code

990-8533

Country

Japan

Facility Name

GSK Investigational Site

City

Yamanashi

ZIP/Postal Code

400-0031

Country

Japan

Facility Name

GSK Investigational Site

City

Yamanashi

ZIP/Postal Code

400-8506

Country

Japan

Facility Name

GSK Investigational Site

City

Bucheon city, Gyenggi-do

ZIP/Postal Code

420-767

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Cheongju-si, Chungcheongbuk-do

ZIP/Postal Code

361-763

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Gyeonggi-do

ZIP/Postal Code

410-719

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Gyeonggi-do

ZIP/Postal Code

431-796

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Gyeonggi-do

ZIP/Postal Code

463-707

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Incheon

ZIP/Postal Code

403-720

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Incheon

ZIP/Postal Code

405-760

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Jeonju-si

ZIP/Postal Code

561-712

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Kangwon-do

ZIP/Postal Code

220-701

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

110-744

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

120-752

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

130-709

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

130-872

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

134-791

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

134-814

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

135-720

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

136-705

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

143-729

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

150-713

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

156-707

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

156-755

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

158-710

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Suwon

ZIP/Postal Code

442-723

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Alkmaar

ZIP/Postal Code

1815 JD

Country

Netherlands

Facility Name

GSK Investigational Site

City

Almelo

ZIP/Postal Code

7606 SB

Country

Netherlands

Facility Name

GSK Investigational Site

City

Almelo

ZIP/Postal Code

7609 PP

Country

Netherlands

Facility Name

GSK Investigational Site

City

Assen

ZIP/Postal Code

9401 RK

Country

Netherlands

Facility Name

GSK Investigational Site

City

Beek

ZIP/Postal Code

6191 JW

Country

Netherlands

Facility Name

GSK Investigational Site

City

Breda

ZIP/Postal Code

4818 CK

Country

Netherlands

Facility Name

GSK Investigational Site

City

Den Bosch

ZIP/Postal Code

5223 GZ

Country

Netherlands

Facility Name

GSK Investigational Site

City

Dordrecht

ZIP/Postal Code

3318 AT

Country

Netherlands

Facility Name

GSK Investigational Site

City

Eindhoven

ZIP/Postal Code

5623 EJ

Country

Netherlands

Facility Name

GSK Investigational Site

City

Enschede

ZIP/Postal Code

7513 ER

Country

Netherlands

Facility Name

GSK Investigational Site

City

Groningen

ZIP/Postal Code

9728 NT

Country

Netherlands

Facility Name

GSK Investigational Site

City

Harderwijk

ZIP/Postal Code

3844 DG

Country

Netherlands

Facility Name

GSK Investigational Site

City

Helmond

ZIP/Postal Code

5707 HA

Country

Netherlands

Facility Name

GSK Investigational Site

City

Hoofddorp

ZIP/Postal Code

2134 TM

Country

Netherlands

Facility Name

GSK Investigational Site

City

Hoorn

ZIP/Postal Code

1624 NP

Country

Netherlands

Facility Name

GSK Investigational Site

City

Kloosterhaar

ZIP/Postal Code

7694 AC

Country

Netherlands

Facility Name

GSK Investigational Site

City

Leeuwarden

ZIP/Postal Code

8934 AD

Country

Netherlands

Facility Name

GSK Investigational Site

City

Nieuwegein

ZIP/Postal Code

3435 CM

Country

Netherlands

Facility Name

GSK Investigational Site

City

Rotterdam

ZIP/Postal Code

3083 AN

Country

Netherlands

Facility Name

GSK Investigational Site

City

Sneek

ZIP/Postal Code

8601 ZR

Country

Netherlands

Facility Name

GSK Investigational Site

City

Spijkenisse

ZIP/Postal Code

3207 NB

Country

Netherlands

Facility Name

GSK Investigational Site

City

Veldhoven

ZIP/Postal Code

5504 DB

Country

Netherlands

Facility Name

GSK Investigational Site

City

Zutphen

ZIP/Postal Code

7207 AE

Country

Netherlands

Facility Name

GSK Investigational Site

City

Zwolle

ZIP/Postal Code

8025 AB

Country

Netherlands

Facility Name

GSK Investigational Site

City

Auckland

ZIP/Postal Code

1051

Country

New Zealand

Facility Name

GSK Investigational Site

City

Dunedin

ZIP/Postal Code

9012

Country

New Zealand

Facility Name

GSK Investigational Site

City

Newtown, Wellington

ZIP/Postal Code

6021

Country

New Zealand

Facility Name

GSK Investigational Site

City

Tauranga

ZIP/Postal Code

3110

Country

New Zealand

Facility Name

GSK Investigational Site

City

Tauranga

ZIP/Postal Code

3112

Country

New Zealand

Facility Name

GSK Investigational Site

City

Wellington

ZIP/Postal Code

6021

Country

New Zealand

Facility Name

GSK Investigational Site

City

Bodø

ZIP/Postal Code

8005

Country

Norway

Facility Name

GSK Investigational Site

City

Fredrikstad

ZIP/Postal Code

1606

Country

Norway

Facility Name

GSK Investigational Site

City

Hakadal

ZIP/Postal Code

1487

Country

Norway

Facility Name

GSK Investigational Site

City

Kløfta

ZIP/Postal Code

2040

Country

Norway

Facility Name

GSK Investigational Site

City

Levanger

ZIP/Postal Code

7600

Country

Norway

Facility Name

GSK Investigational Site

City

Oslo

ZIP/Postal Code

0953

Country

Norway

Facility Name

GSK Investigational Site

City

Stavanger

ZIP/Postal Code

4005

Country

Norway

Facility Name

GSK Investigational Site

City

Stavanger

ZIP/Postal Code

4011

Country

Norway

Facility Name

GSK Investigational Site

City

Trondheim

ZIP/Postal Code

7027

Country

Norway

Facility Name

GSK Investigational Site

City

Pueblo Libre

State/Province

Lima

ZIP/Postal Code

Lima 21

Country

Peru

Facility Name

GSK Investigational Site

City

San Martin de Porres

State/Province

Lima

ZIP/Postal Code

Lima 31

Country

Peru

Facility Name

GSK Investigational Site

City

San Miguel

State/Province

Lima

ZIP/Postal Code

Lima 32

Country

Peru

Facility Name

GSK Investigational Site

City

Lima

ZIP/Postal Code

Country

Peru

Facility Name

GSK Investigational Site

City

Lima

ZIP/Postal Code

L 33

Country

Peru

Facility Name

GSK Investigational Site

City

Lima

ZIP/Postal Code

L41

Country

Peru

Facility Name

GSK Investigational Site

City

Lima

ZIP/Postal Code

Lima 14

Country

Peru

Facility Name

GSK Investigational Site

City

Lima

ZIP/Postal Code

Lima 18

Country

Peru

Facility Name

GSK Investigational Site

City

Lima

ZIP/Postal Code

Lima 1

Country

Peru

Facility Name

GSK Investigational Site

City

Lima

ZIP/Postal Code

Lima 27

Country

Peru

Facility Name

GSK Investigational Site

City

Lima

ZIP/Postal Code

Lima 32

Country

Peru

Facility Name

GSK Investigational Site

City

Lima

ZIP/Postal Code

Lima 41

Country

Peru

Facility Name

GSK Investigational Site

City

Caloocan City

ZIP/Postal Code

1400

Country

Philippines

Facility Name

GSK Investigational Site

City

Iloilo

ZIP/Postal Code

5000

Country

Philippines

Facility Name

GSK Investigational Site

City

Jaro, Iloilo City

ZIP/Postal Code

5000

Country

Philippines

Facility Name

GSK Investigational Site

City

Pasig

ZIP/Postal Code

1605

Country

Philippines

Facility Name

GSK Investigational Site

City

Quezon City

ZIP/Postal Code

1100

Country

Philippines

Facility Name

GSK Investigational Site

City

Bialystok

ZIP/Postal Code

15-351

Country

Poland

Facility Name

GSK Investigational Site

City

Ostrowiec Swietokrzyski

ZIP/Postal Code

27-400

Country

Poland

Facility Name

GSK Investigational Site

City

Sopot

ZIP/Postal Code

81-741

Country

Poland

Facility Name

GSK Investigational Site

City

Szczecin

ZIP/Postal Code

71-124

Country

Poland

Facility Name

GSK Investigational Site

City

Tarnów

ZIP/Postal Code

33-100

Country

Poland

Facility Name

GSK Investigational Site

City

Zgierz

ZIP/Postal Code

95-100

Country

Poland

Facility Name

GSK Investigational Site

City

Guaynabo

ZIP/Postal Code

00968

Country

Puerto Rico

Facility Name

GSK Investigational Site

City

Mayaguez

ZIP/Postal Code

00680

Country

Puerto Rico

Facility Name

GSK Investigational Site

City

Ponce

ZIP/Postal Code

00716

Country

Puerto Rico

Facility Name

GSK Investigational Site

City

San Juan

ZIP/Postal Code

00921

Country

Puerto Rico

Facility Name

GSK Investigational Site

City

San Juan

ZIP/Postal Code

00927

Country

Puerto Rico

Facility Name

GSK Investigational Site

City

Braila

ZIP/Postal Code

810003

Country

Romania

Facility Name

GSK Investigational Site

City

Brasov

ZIP/Postal Code

500283

Country

Romania

Facility Name

GSK Investigational Site

City

Bucharest

ZIP/Postal Code

020125

Country

Romania

Facility Name

GSK Investigational Site

City

Comuna Alexandru Cel Bun

ZIP/Postal Code

617507

Country

Romania

Facility Name

GSK Investigational Site

City

Constanta

ZIP/Postal Code

900002

Country

Romania

Facility Name

GSK Investigational Site

City

Ploiesti

ZIP/Postal Code

100184

Country

Romania

Facility Name

GSK Investigational Site

City

Ploiesti

ZIP/Postal Code

100379

Country

Romania

Facility Name

GSK Investigational Site

City

Ramnicu Valcea

ZIP/Postal Code

240564

Country

Romania

Facility Name

GSK Investigational Site

City

Barnaul

ZIP/Postal Code

656038

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Belgorod

ZIP/Postal Code

308007

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Blagoveshchensk

ZIP/Postal Code

675000

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Chita

ZIP/Postal Code

672000

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Chita

ZIP/Postal Code

672090

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Ekaterinburg

ZIP/Postal Code

620109

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Ivanovo

ZIP/Postal Code

153005

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Kazan

ZIP/Postal Code

420012

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Kazan

ZIP/Postal Code

420015

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Krasnodar

ZIP/Postal Code

350012

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Krasnoyarsk

ZIP/Postal Code

660022

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Moscow

ZIP/Postal Code

119002

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Moscow

ZIP/Postal Code

127018

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Novgorod

ZIP/Postal Code

173008

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Novosibirsk

ZIP/Postal Code

630087

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Petrozavodsk

ZIP/Postal Code

185019

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Pyatigorsk

ZIP/Postal Code

357538

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Ryazan

ZIP/Postal Code

390005

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Ryazan

ZIP/Postal Code

390039

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Saint-Petersburg

ZIP/Postal Code

194354

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Saratov

ZIP/Postal Code

410053

Country

Russian Federation

Facility Name

GSK Investigational Site

City

St. Petersburg

ZIP/Postal Code

194356

Country

Russian Federation

Facility Name

GSK Investigational Site

City

St. Petersburg

ZIP/Postal Code

198216

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Stavropol

ZIP/Postal Code

355017

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Tomsk

ZIP/Postal Code

634009

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Tomsk

ZIP/Postal Code

634050

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Ulan-Ude

ZIP/Postal Code

670031

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Ulyanovsk

ZIP/Postal Code

432063

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Vladimir

ZIP/Postal Code

600023

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Vladivostok

ZIP/Postal Code

690002

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Vladivostok

ZIP/Postal Code

690950

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Volgodonsk

ZIP/Postal Code

347381

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Voronezh

ZIP/Postal Code

394066

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Vsevolozhsk, Leningrad Region

ZIP/Postal Code

188640

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Yaroslavl

ZIP/Postal Code

150003

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Yaroslavl

ZIP/Postal Code

150010

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Singapore

ZIP/Postal Code

117599

Country

Singapore

Facility Name

GSK Investigational Site

City

Singapore

ZIP/Postal Code

169856

Country

Singapore

Facility Name

GSK Investigational Site

City

Singapore

ZIP/Postal Code

529889

Country

Singapore

Facility Name

GSK Investigational Site

City

Singapore

ZIP/Postal Code

609606

Country

Singapore

Facility Name

GSK Investigational Site

City

Benoni

State/Province

Gauteng

ZIP/Postal Code

1501

Country

South Africa

Facility Name

GSK Investigational Site

City

Boksburg

State/Province

Gauteng

ZIP/Postal Code

1459

Country

South Africa

Facility Name

GSK Investigational Site

City

Pretoria

State/Province

Gauteng

ZIP/Postal Code

0183

Country

South Africa

Facility Name

GSK Investigational Site

City

Val De Grace, Pretoria

State/Province

Gauteng

ZIP/Postal Code

0184

Country

South Africa

Facility Name

GSK Investigational Site

City

Middelburg

State/Province

Mpumalanga

ZIP/Postal Code

1055

Country

South Africa

Facility Name

GSK Investigational Site

City

Amanzimtoti

ZIP/Postal Code

4126

Country

South Africa

Facility Name

GSK Investigational Site

City

Bellville

ZIP/Postal Code

7530

Country

South Africa

Facility Name

GSK Investigational Site

City

Bloemfontein

ZIP/Postal Code

9301

Country

South Africa

Facility Name

GSK Investigational Site

City

Boksburg North

ZIP/Postal Code

1459

Country

South Africa

Facility Name

GSK Investigational Site

City

Cape Town

ZIP/Postal Code

7129

Country

South Africa

Facility Name

GSK Investigational Site

City

Cape Town

ZIP/Postal Code

7572

Country

South Africa

Facility Name

GSK Investigational Site

City

CapeTown

ZIP/Postal Code

7764

Country

South Africa

Facility Name

GSK Investigational Site

City

Durban

ZIP/Postal Code

4001

Country

South Africa

Facility Name

GSK Investigational Site

City

Durban

ZIP/Postal Code

4091

Country

South Africa

Facility Name

GSK Investigational Site

City

Gatesville

ZIP/Postal Code

7764

Country

South Africa

Facility Name

GSK Investigational Site

City

Johannesburg

ZIP/Postal Code

2113

Country

South Africa

Facility Name

GSK Investigational Site

City

Korsten

ZIP/Postal Code

6014

Country

South Africa

Facility Name

GSK Investigational Site

City

Mowbray

ZIP/Postal Code

7700

Country

South Africa

Facility Name

GSK Investigational Site

City

Paarl

ZIP/Postal Code

7646

Country

South Africa

Facility Name

GSK Investigational Site

City

Panorama

ZIP/Postal Code

7500

Country

South Africa

Facility Name

GSK Investigational Site

City

Tygerberg

ZIP/Postal Code

7505

Country

South Africa

Facility Name

GSK Investigational Site

City

Marbella - Málaga

State/Province

Andalucia

ZIP/Postal Code

29603

Country

Spain

Facility Name

GSK Investigational Site

City

Laredo

State/Province

Cantabria

ZIP/Postal Code

39770

Country

Spain

Facility Name

GSK Investigational Site

City

Torrelavega

State/Province

Cantabria

ZIP/Postal Code

39300

Country

Spain

Facility Name

GSK Investigational Site

City

Badalona

State/Province

Catalonia

ZIP/Postal Code

08916

Country

Spain

Facility Name

GSK Investigational Site

City

(Badalona) Barcelona

ZIP/Postal Code

08911

Country

Spain

Facility Name

GSK Investigational Site

City

(Barakaldo) Vizcaya

ZIP/Postal Code

48903

Country

Spain

Facility Name

GSK Investigational Site

City

Alicante

ZIP/Postal Code

03004

Country

Spain

Facility Name

GSK Investigational Site

City

Alzira/Valencia

ZIP/Postal Code

46600

Country

Spain

Facility Name

GSK Investigational Site

City

Barcelona

ZIP/Postal Code

08003

Country

Spain

Facility Name

GSK Investigational Site

City

Barcelona

ZIP/Postal Code

08006

Country

Spain

Facility Name

GSK Investigational Site

City

Barcelona

ZIP/Postal Code

08017

Country

Spain

Facility Name

GSK Investigational Site

City

Barcelona

ZIP/Postal Code

08023

Country

Spain

Facility Name

GSK Investigational Site

City

Barcelona

ZIP/Postal Code

08028

Country

Spain

Facility Name

GSK Investigational Site

City

Barcelona

ZIP/Postal Code

08035

Country

Spain

Facility Name

GSK Investigational Site

City

Barcelona

ZIP/Postal Code

08036

Country

Spain

Facility Name

GSK Investigational Site

City

Barcelona

ZIP/Postal Code

08041

Country

Spain

Facility Name

GSK Investigational Site

City

Basurto/Bilbao

ZIP/Postal Code

48013

Country

Spain

Facility Name

GSK Investigational Site

City

Burgos

ZIP/Postal Code

09006

Country

Spain

Facility Name

GSK Investigational Site

City

Centelles (Barcelona)

ZIP/Postal Code

08540

Country

Spain

Facility Name

GSK Investigational Site

City

Coslada

ZIP/Postal Code

28822

Country

Spain

Facility Name

GSK Investigational Site

City

Cáceres

ZIP/Postal Code

10003

Country

Spain

Facility Name

GSK Investigational Site

City

Gerona

ZIP/Postal Code

17005

Country

Spain

Facility Name

GSK Investigational Site

City

Girona

ZIP/Postal Code

17007

Country

Spain

Facility Name

GSK Investigational Site

City

L'Hospitalet de Llobregat

ZIP/Postal Code

08907

Country

Spain

Facility Name

GSK Investigational Site

City

La Coruña

ZIP/Postal Code

15006

Country

Spain

Facility Name

GSK Investigational Site

City

La Coruña

ZIP/Postal Code

15011

Country

Spain

Facility Name

GSK Investigational Site

City

La Roca Del Valles (Barcelona)

ZIP/Postal Code

08430

Country

Spain

Facility Name

GSK Investigational Site

City

Lleida

ZIP/Postal Code

25198

Country

Spain

Facility Name

GSK Investigational Site

City

Madrid

ZIP/Postal Code

28006

Country

Spain

Facility Name

GSK Investigational Site

City

Madrid

ZIP/Postal Code

28040

Country

Spain

Facility Name

GSK Investigational Site

City

Mataró

ZIP/Postal Code

08303

Country

Spain

Facility Name

GSK Investigational Site

City

Málaga

ZIP/Postal Code

29010

Country

Spain

Facility Name

GSK Investigational Site

City

Mérida (Badajoz)

ZIP/Postal Code

06800

Country

Spain

Facility Name

GSK Investigational Site

City

Oviedo

ZIP/Postal Code

33006

Country

Spain

Facility Name

GSK Investigational Site

City

Palma de Mallorca

ZIP/Postal Code

07120

Country

Spain

Facility Name

GSK Investigational Site

City

Pamplona

ZIP/Postal Code

31008

Country

Spain

Facility Name

GSK Investigational Site

City

Peralada( Girona)

ZIP/Postal Code

17491

Country

Spain

Facility Name

GSK Investigational Site

City

Petrer/Alicante

ZIP/Postal Code

03610

Country

Spain

Facility Name

GSK Investigational Site

City

Ponferrada (León)

ZIP/Postal Code

24411

Country

Spain

Facility Name

GSK Investigational Site

City

Pozuelo De Alarcón/Madrid

ZIP/Postal Code

28223

Country

Spain

Facility Name

GSK Investigational Site

City

Sabadell (Barcelona)

ZIP/Postal Code

08208

Country

Spain

Facility Name

GSK Investigational Site

City

Sagunto/Valencia

ZIP/Postal Code

46520

Country

Spain

Facility Name

GSK Investigational Site

City

Salamanca

ZIP/Postal Code

37007

Country

Spain

Facility Name

GSK Investigational Site

City

San Juan De Alicante

ZIP/Postal Code

3550

Country

Spain

Facility Name

GSK Investigational Site

City

San Sebastian de los Reyes

ZIP/Postal Code

28702

Country

Spain

Facility Name

GSK Investigational Site

City

Santander

ZIP/Postal Code

39008

Country

Spain

Facility Name

GSK Investigational Site

City

Santiago de Compostela

ZIP/Postal Code

15706

Country

Spain

Facility Name

GSK Investigational Site

City

Sevilla

ZIP/Postal Code

41013

Country

Spain

Facility Name

GSK Investigational Site

City

Tarragona

ZIP/Postal Code

43002

Country

Spain

Facility Name

GSK Investigational Site

City

Valencia

ZIP/Postal Code

46015

Country

Spain

Facility Name

GSK Investigational Site

City

Valencia

ZIP/Postal Code

46017

Country

Spain

Facility Name

GSK Investigational Site

City

Valladolid

ZIP/Postal Code

47012

Country

Spain

Facility Name

GSK Investigational Site

City

Vizcaya

ZIP/Postal Code

48902

Country

Spain

Facility Name

GSK Investigational Site

City

Zaragoza

ZIP/Postal Code

50009

Country

Spain

Facility Name

GSK Investigational Site

City

Borås

ZIP/Postal Code

SE-506 30

Country

Sweden

Facility Name

GSK Investigational Site

City

Göteborg

ZIP/Postal Code

SE-413 45

Country

Sweden

Facility Name

GSK Investigational Site

City

Göteborg

ZIP/Postal Code

SE-413 90

Country

Sweden

Facility Name

GSK Investigational Site

City

Höllviken

ZIP/Postal Code

SE-236 32

Country

Sweden

Facility Name

GSK Investigational Site

City

Linköping

ZIP/Postal Code

SE-587 58

Country

Sweden

Facility Name

GSK Investigational Site

City

Luleå

ZIP/Postal Code

SE-971 89

Country

Sweden

Facility Name

GSK Investigational Site

City

Stockholm

ZIP/Postal Code

SE-111 57

Country

Sweden

Facility Name

GSK Investigational Site

City

Uppsala

ZIP/Postal Code

SE-752 37

Country

Sweden

Facility Name

GSK Investigational Site

City

Örebro

ZIP/Postal Code

SE-703 62

Country

Sweden

Facility Name

GSK Investigational Site

City

Östersund

ZIP/Postal Code

SE-831 83

Country

Sweden

Facility Name

GSK Investigational Site

City

Bangkok

ZIP/Postal Code

10330

Country

Thailand

Facility Name

GSK Investigational Site

City

Bangkok

ZIP/Postal Code

10600

Country

Thailand

Facility Name

GSK Investigational Site

City

Chiangmai

ZIP/Postal Code

50200

Country

Thailand

Facility Name

GSK Investigational Site

City

Khon Kaen

ZIP/Postal Code

40002

Country

Thailand

Facility Name

GSK Investigational Site

City

Muang

ZIP/Postal Code

11000

Country

Thailand

Facility Name

GSK Investigational Site

City

Nakhon Ratchasima

ZIP/Postal Code

30000

Country

Thailand

Facility Name

GSK Investigational Site

City

Nan

ZIP/Postal Code

55000

Country

Thailand

Facility Name

GSK Investigational Site

City

Songkla

ZIP/Postal Code

90110

Country

Thailand

Facility Name

GSK Investigational Site

City

Ankara

ZIP/Postal Code

06100

Country

Turkey

Facility Name

GSK Investigational Site

City

Istanbul

ZIP/Postal Code

34020

Country

Turkey

Facility Name

GSK Investigational Site

City

Istanbul

ZIP/Postal Code

34844

Country

Turkey

Facility Name

GSK Investigational Site

City

Izmir

ZIP/Postal Code

35100

Country

Turkey

Facility Name

GSK Investigational Site

City

Mersin

ZIP/Postal Code

33343

Country

Turkey

Facility Name

GSK Investigational Site

City

Kharkiv

ZIP/Postal Code

61002

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kharkiv

ZIP/Postal Code

61124

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kiev

ZIP/Postal Code

03680

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kyiv

ZIP/Postal Code

02232

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kyiv

ZIP/Postal Code

03049

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kyiv

ZIP/Postal Code

03680

Country

Ukraine

Facility Name

GSK Investigational Site

City

Mykolayiv

ZIP/Postal Code

54003

Country

Ukraine

Facility Name

GSK Investigational Site

City

Odesa

ZIP/Postal Code

65025

Country

Ukraine

Facility Name

GSK Investigational Site

City

Sumy

ZIP/Postal Code

40022

Country

Ukraine

Facility Name

GSK Investigational Site

City

Vinnytsia

ZIP/Postal Code

21000

Country

Ukraine

Facility Name

GSK Investigational Site

City

Exeter

State/Province

Devon

ZIP/Postal Code

EX2 5DW

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Wishaw

State/Province

Lanarkshire

ZIP/Postal Code

ML2 0DP

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Blackpool

State/Province

Lancashire

ZIP/Postal Code

FY3 7EN

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Northwood

State/Province

Middlesex

ZIP/Postal Code

HA6 2RN

Country

United Kingdom

Facility Name

GSK Investigational Site

City

High Heaton, Newcastle Upon Tyne

State/Province

Tyne & Wear

ZIP/Postal Code

NE7 7DN

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Bradford on Avon

State/Province

Wiltshire

ZIP/Postal Code

BA15 1DQ

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Baillieston, Glasgow

ZIP/Postal Code

G69 7AD

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Bradford

ZIP/Postal Code

BD9 6RJ

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Cambridge

ZIP/Postal Code

CB2 0QQ

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Chester

ZIP/Postal Code

CH2 1UL

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Crawley

ZIP/Postal Code

RH10 7DX

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Crownhill, Plymouth

ZIP/Postal Code

PL5 3JB

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Dundee, Scotland

ZIP/Postal Code

DD1 9SY

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Sidcup, Kent

ZIP/Postal Code

DA14 6LT

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Stockton-on-Tees

ZIP/Postal Code

TS19 8PE

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Trowbridge

ZIP/Postal Code

BA14 9AR

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Ha Noi

ZIP/Postal Code

10000

Country

Vietnam

Facility Name

GSK Investigational Site

City

Ho Chi Minh

ZIP/Postal Code

70000

Country

Vietnam

12. IPD Sharing Statement

Citations:

PubMed Identifier

36102236

Citation

Dransfield MT, Criner GJ, Halpin DMG, Han MK, Hartley B, Kalhan R, Lange P, Lipson DA, Martinez FJ, Midwinter D, Singh D, Wise R, Kunisaki KM. Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial. J Am Heart Assoc. 2022 Sep 20;11(18):e024350. doi: 10.1161/JAHA.121.024350. Epub 2022 Sep 14.

Results Reference

derived

PubMed Identifier

34972260

Citation

Thomashow B, Stiegler M, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lange P, Martinez FJ, Midwinter D, Singh D, Tabberer M, Wise RA, Lipson DA, Jones P. Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial. Chronic Obstr Pulm Dis. 2022 Jan 27;9(1):68-79. doi: 10.15326/jcopdf.2021.0259.

Results Reference

derived

PubMed Identifier

34385263

Citation

Bafadhel M, Barnes N, Bourke SC, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Jones CE, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, Martinez FJ, Wise R, Singh D. A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. Eur Respir J. 2021 Sep 23;58(3):2004522. doi: 10.1183/13993003.04522-2020. Print 2021 Sep. No abstract available.

Results Reference

derived

PubMed Identifier

33910578

Citation

Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lange P, Lettis S, Lipson DA, Mannino D, Martin N, Martinez FJ, Miller BE, Wise R, Zhu CQ, Lomas D. InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respir Res. 2021 Apr 28;22(1):130. doi: 10.1186/s12931-021-01706-y.

Results Reference

derived

PubMed Identifier

33201438

Citation

Halpin DMG, Criner GJ, Dransfield MT, Han MK, Hartley B, Harvey C, Jones CE, Kato M, Lange P, Lettis S, Lomas DA, Martinez FJ, Martin N, Singh D, Wise R, Zheng J, Lipson DA. Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. Pulm Ther. 2021 Jun;7(1):101-118. doi: 10.1007/s41030-020-00136-3. Epub 2020 Nov 17.

Results Reference

derived

PubMed Identifier

33156982

Citation

Bourdin A, Criner G, Devouassoux G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kalhan R, Lange P, Lettis S, Lipson DA, Lomas DA, Echave-Sustaeta Maria-Tome JM, Martin N, Martinez FJ, Quasny H, Sail L, Siler TM, Singh D, Thomashow B, Watz H, Wise R, Hanania NA. InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions. Chronic Obstr Pulm Dis. 2021 Jan;8(1):76-90. doi: 10.15326/jcopdf.2020.0158.

Results Reference

derived

PubMed Identifier

33124900

Citation

Zheng J, Zhong N, Wang C, Wei LP, Zhou XD, Zhao L, Dong Yuan Y, He B, Wu B, Du X, Song J, Lipson DA. Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial. Curr Med Res Opin. 2021 Jan;37(1):145-155. doi: 10.1080/03007995.2020.1844646. Epub 2020 Dec 7.

Results Reference

derived

PubMed Identifier

33121372

Citation

Marin JM, Mateos L, Roldan J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, Velasco B, Jones CE, Kilbride S, Lipson DA. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963021. doi: 10.1177/1753466620963021.

Results Reference

derived

PubMed Identifier

33031829

Citation

Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Chest. 2021 Mar;159(3):985-995. doi: 10.1016/j.chest.2020.09.253. Epub 2020 Oct 5.

Results Reference

derived

PubMed Identifier

32647911

Citation

Tabberer M, Jones CE, Kilbride S, Halpin DMG, Lomas DA, Pascoe S, Singh D, Wise RA, Criner GJ, Lange P, Dransfield MT, Han MK, Martinez FJ, Kaisermann MC, Lipson DA. Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. Adv Ther. 2020 Sep;37(9):3775-3790. doi: 10.1007/s12325-020-01409-8. Epub 2020 Jul 9. Erratum In: Adv Ther. 2022 Mar;39(3):1446.

Results Reference

derived

PubMed Identifier

32584168

Citation

Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, Wise RA, Singh D, Martinez FJ. The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. Am J Respir Crit Care Med. 2020 Nov 1;202(9):1237-1243. doi: 10.1164/rccm.201912-2478OC.

Results Reference

derived

PubMed Identifier

32503599

Citation

Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, Lomas DA, Martin N, Martinez FJ, Singh D, Wise R, Lipson DA. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respir Res. 2020 Jun 5;21(1):139. doi: 10.1186/s12931-020-01398-w.

Results Reference

derived

PubMed Identifier

32436683

Citation

Bogart MR, Hopson SD, Shih HC, Stanford RH, Coutinho AD. COPD exacerbation costs in the IMPACT study: a within-trial analysis. Am J Manag Care. 2020 May 1;26(5):e150-e154. doi: 10.37765/ajmc.2020.43157.

Results Reference

derived

PubMed Identifier

32299860

Citation

Halpin DMG, Dransfield MT, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, Martinez FJ, Pascoe S, Singh D, Wise R, Criner GJ. The effect of exacerbation history on outcomes in the IMPACT trial. Eur Respir J. 2020 May 21;55(5):1901921. doi: 10.1183/13993003.01921-2019. Print 2020 May. Erratum In: Eur Respir J. 2020 Jun 18;55(6):

Results Reference

derived

PubMed Identifier

32162970

Citation

Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Lettis S, Manchester P, Martin N, Midwinter D, Morris A, Pascoe SJ, Singh D, Wise RA, Martinez FJ. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC.

Results Reference

derived

PubMed Identifier

31819401

Citation

Ismaila AS, Risebrough N, Schroeder M, Shah D, Martin A, Goodall EC, Ndirangu K, Criner G, Dransfield M, Halpin DM, Han MK, Lomas DA. Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial. Int J Chron Obstruct Pulmon Dis. 2019 Nov 29;14:2681-2695. doi: 10.2147/COPD.S216072. eCollection 2019.

Results Reference

derived

PubMed Identifier

31321713

Citation

Mehta R, Farrell C, Hayes S, Birk R, Okour M, Lipson DA. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Clin Pharmacokinet. 2020 Jan;59(1):67-79. doi: 10.1007/s40262-019-00794-w.

Results Reference

derived

PubMed Identifier

31281061

Citation

Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019 Sep;7(9):745-756. doi: 10.1016/S2213-2600(19)30190-0. Epub 2019 Jul 4. Erratum In: Lancet Respir Med. 2021 Dec;9(12):e114.

Results Reference

derived

PubMed Identifier

29668352

Citation

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.

Results Reference

derived

PubMed Identifier

27418551

Citation

Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, Dransfield MT, Pavord I, Barnes N. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016 Aug;48(2):320-30. doi: 10.1183/13993003.02165-2015. Epub 2016 Jul 13.

Results Reference

derived

Learn more about this trial

We'll reach out to this number within 24 hrs

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial